Pressure BioSciences (PBIO) 10-K 12 Apr 23 2022 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Dec. 31, 2022	Mar. 31, 2023	Jun. 30, 2022
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2022
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	001-38185
Entity Registrant Name	PRESSURE BIOSCIENCES, INC.
Entity Central Index Key	0000830656
Entity Tax Identification Number	04-2652826
Entity Incorporation, State or Country Code	MA
Entity Address, Address Line One	14 Norfolk Avenue
Entity Address, City or Town	South Easton
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02375
City Area Code	508
Local Phone Number	230-1828
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 17,966,105
Entity Common Stock, Shares Outstanding		15,867,711
Auditor Firm ID	206
Auditor Name	MaloneBailey, LLP
Auditor Location	Houston, Texas

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2022	Dec. 31, 2021
CURRENT ASSETS
Cash and cash equivalents	$ 3,865	$ 132,311
Accounts receivable	295,374	154,746
Inventories, net of $982,973 and $342,496 reserve, respectively	686,383	1,147,554
Prepaid expenses and other current assets	257,527	422,617
Total current assets	1,243,149	1,857,228
Investment in equity securities	63,638	59,976
Property and equipment, net	103,351	115,846
Right of use asset operating leases	282,095	395,565
Intangible assets, net	317,308	403,846
TOTAL ASSETS	2,009,541	2,832,461
CURRENT LIABILITIES
Accounts payable	637,238	527,924
Accrued employee compensation	167,247	117,680
Accrued professional fees and other	2,497,762	1,955,672
Accrued interest and dividends payable	10,803,983	7,757,217
Deferred revenue	58,242	37,124
Convertible debt, net of unamortized debt discounts of $455,517 and $1,536,649, respectively	17,823,669	12,839,813
Other debt, net of unamortized discounts of $0 and $0, respectively	1,638,969	1,256,840
Related party debt, net of unamortized debt discount of $7,915 and $0, respectively	634,885
Right of use operating lease liability	142,171	132,996
Total current liabilities	34,404,166	24,625,266
LONG TERM LIABILITIES
Long term debt	150,000	150,000
Right of use operating lease liability long term	139,924	262,569
Deferred revenue	1,822	3,587
TOTAL LIABILITIES	34,695,912	25,041,422
COMMITMENTS AND CONTINGENCIES (Note 8)
STOCKHOLDERS’ DEFICIT
Series D, G, H, H2, J, K, AA Convertible Preferred Stock, $.01 par value (Note 10)	1,098	1,099
Common stock, $.01 par value; 100,000,000 shares authorized; 13,682,910 and 9,120,526 shares issued and outstanding on December 31, 2022 and December 31, 2021, respectively	136,829	91,206
Warrants to acquire common stock	31,995,762	31,715,154
Additional paid-in capital	69,006,145	64,261,048
Accumulated deficit	(133,826,205)	(118,277,468)
TOTAL STOCKHOLDERS’ DEFICIT	(32,686,371)	(22,208,961)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$ 2,009,541	$ 2,832,461

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Inventory valuation reserves	$ 982,973	$ 342,496
Debt instrument, unamortized discount	455,517	1,536,649
Other debt, unamortized discounts net	$ 0	$ 0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares, issued	13,682,910	9,120,526
Common stock, shares, outstanding	13,682,910	9,120,526
Series D Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Series G Convertible Preferred Stock [Member]
Preferred stock, par value	0.01	0.01
Series H Convertible Preferred Stock [Member]
Preferred stock, par value	0.01	0.01
Series H2 Convertible Preferred Stock [Member]
Preferred stock, par value	0.01	0.01
Series J Convertible Preferred Stock [Member]
Preferred stock, par value	0.01	0.01
Series K Convertible Preferred Stock [Member]
Preferred stock, par value	0.01	0.01
Series AA Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Convertible Debt [Member]
Debt instrument, unamortized discount	$ 455,517	$ 1,536,649
Related Party [Member]
Debt instrument, unamortized discount	$ 7,915	$ 0

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Revenue:
Products, services, other	$ 1,729,343	$ 2,002,365
Total revenue	1,729,343	2,002,365
Costs and expenses:
Cost of products and services	2,014,004	942,383
Research and development	969,532	1,101,509
Selling and marketing	401,444	324,728
General and administrative	3,242,652	3,818,892
Total operating costs	6,627,632	6,187,512
Operating loss	(4,898,289)	(4,185,147)
Other (expense) income:
Interest expense, net	(10,438,565)	(14,450,241)
Unrealized (loss) gain on investment in equity securities	3,662	(457,025)
Gain (loss) on extinguishment of liabilities	(751,335)	(1,061,073)
Other income (expense)	7,849
Total other expense	(11,178,389)	(15,968,339)
Net loss	(16,076,678)	(20,153,486)
Deemed dividends on beneficial conversion feature		(873,798)
Preferred stock dividends	(1,727,275)	(1,658,175)
Net loss attributable to common shareholders	$ (17,803,953)	$ (22,685,459)
Basic and diluted net loss per share attributable to common shareholders	$ (1.61)	$ (3.42)
Weighted average common shares outstanding used in the basic and diluted net loss per share calculation	11,058,356	6,636,523

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Deficit - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Warrant [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2020	$ 1,093	$ 41,683	$ 29,192,471	$ 50,312,968	$ (96,465,807)	$ (16,917,592)
Beginning balance, shares at Dec. 31, 2020	109,272	4,168,324
Stock-based compensation				254,615		254,615
Stock option exercise		$ 214		14,559		$ 14,773
Stock option exercise, shares		21,411	187,500			208,911
Issuance of common stock for non-cash warrant exercise		$ 363	$ (343,201)	342,838
Issuance of common stock for non-cash warrant exercise, shares		36,290
Beneficial conversion feature on debt				1,320,331		1,320,331
Beneficial conversion option on convertible preferred stock				873,798		873,798
Deemed dividend on convertible preferred stock				(873,798)		(873,798)
Preferred stock issued for debt settlement	$ 2		245,635	277,617		523,254
Preferred stock issued for debt settlement, share	200
Conversion of debt and interest for common stock		$ 11,960		2,978,030		2,989,990
Conversion of debt and interest for common stock, shares		1,195,996
Issuance of common stock for dividends paid-in-kind		$ 823		183,451		184,274
Issuance of common stock for dividends paid-in-kind, shares		82,373
Issuance of common stock for interest paid-in-kind		$ 28,835		6,636,821		6,665,656
Issuance of common stock for interest paid-in-kind, shares		2,883,282
Issuance of common stock for services		$ 3,332		791,230		$ 794,562
Issuance of common stock for services, shares		333,200				333,200
Stock issued with debt		$ 3,996		642,722		$ 646,718
Stock issued with debt, shares		399,650
Series AA Preferred Stock offering	$ 4		509,130	505,866		1,015,000
Series AA Preferred Stock offering, shares	406
Series AA Preferred Stock dividend					(1,658,175)	(1,658,175)
Issuance of common stock warrants for interest paid-in-kind			600,298			600,298
Warrants issued with debt			1,403,546			1,403,546
Warrants issued with debt settlement			107,275			107,275
Net loss					(20,153,486)	(20,153,486)
Common stock issued for debt extension, shares			2,235,408
Ending balance, value at Dec. 31, 2021	$ 1,099	$ 91,206	$ 31,715,154	64,261,048	(118,277,468)	(22,208,961)
Ending balance, shares at Dec. 31, 2021	109,878	9,120,526
Stock-based compensation				215,098		215,098
Stock option exercise		$ 253		17,190		$ 17,443
Stock option exercise, shares		25,279				25,279
Conversion of debt and interest for common stock		$ 1,819		465,273		$ 467,092
Conversion of debt and interest for common stock, shares		181,918				181,918
Issuance of common stock for dividends paid-in-kind		$ 2,361		383,939		$ 386,300
Issuance of common stock for dividends paid-in-kind, shares		236,221
Issuance of common stock for interest paid-in-kind		$ 17,663		2,925,476		2,943,139
Issuance of common stock for interest paid-in-kind, shares		1,766,266
Issuance of common stock for services		$ 2,555		389,620		$ 392,175
Issuance of common stock for services, shares		255,500				255,500
Stock issued with debt		$ 6,590		867,264		$ 873,854
Stock issued with debt, shares		659,000
Series AA Preferred Stock dividend					(1,727,275)	(1,727,275)
Warrants issued with debt			93,576			93,576
Net loss					(16,076,678)	(16,076,678)
Early adoption of ASU 2020-06				(2,728,243)	2,255,216	(473,027)
Warrants issued for debt extension			132,537			132,537
Common stock issued for debt extension		$ 14,238		2,184,623		$ 2,198,861
Common stock issued for debt extension, shares		1,423,800	277,500			10,000
Conversion of preferred stock for common stock	$ (1)	$ 44		(43)
Conversion of preferred stock for common stock, shares	(4)	4,400
Sale of common stock for cash		$ 100		24,900		25,000
Stock issued with debt, shares		10,000
Warrants issued for services			54,495			54,495
Ending balance, value at Dec. 31, 2022	$ 1,098	$ 136,829	$ 31,995,762	$ 69,006,145	$ (133,826,205)	$ (32,686,371)
Ending balance, shares at Dec. 31, 2022	109,874	13,682,910

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (16,076,678)	$ (20,153,486)
Adjustments to reconcile net loss to net cash used in operating activities:
Gain on loan forgiveness	(10,000)	(734,077)
Non-cash lease expense	113,470	65,194
Common stock and warrants issued for interest	2,943,139	7,265,954
Depreciation and amortization	119,788	110,128
Accretion of interest and amortization of debt discount	1,777,863	6,738,802
Common stock and warrants issued for debt extension	2,331,398	130,279
Allowance for inventory reserve	641,815
Stock-based compensation expense	215,098	254,615
(Gain) loss on investment in equity securities	(3,662)	457,025
Common stock and warrants issued for services	446,670	794,562
Changes in operating assets and liabilities:
Accounts receivable	(140,628)	(23,518)
Inventories	(180,644)	(554,787)
Prepaid expenses and other assets	165,090	(107,681)
Accounts payable	109,314	(226,771)
Accrued employee compensation	49,567	15,106
Operating lease liability	(113,470)	(65,194)
Deferred revenue and other accrued expenses	3,133,829	1,165,276
Net cash used in operating activities	(4,478,041)	(4,868,573)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property plant and equipment	(20,755)	(122,945)
Net cash used in investing activities	(20,755)	(122,945)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from the issuance of Series AA Convertible Preferred Stock		1,015,000
Sale of common stock	25,000
Proceeds from stock option exercises	17,443	14,773
Net proceeds from convertible debt	4,907,222	5,514,250
Net proceeds from non-convertible debt - third party	2,710,000	2,010,688
Net proceeds from non-convertible debt - related party	866,350	254,600
Payments on convertible debt	(1,522,494)	(1,833,295)
Payments on non-convertible debt - related party	(315,300)	(354,600)
Payments on non-convertible debt	(2,317,871)	(1,516,127)
Net cash provided by financing activities	4,370,350	5,105,289
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(128,446)	113,771
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR	132,311	18,540
CASH AND CASH EQUIVALENTS AT END OF YEAR	3,865	132,311
SUPPLEMENTAL INFORMATION
Interest paid in cash	1,378,647	921,569
NON CASH TRANSACTIONS:
Common stock issued for non-cash warrant exercise		363
Early ASU 2020-06 adoption	473,027
Common stock issued with debt	873,854	646,718
Discount from warrants issued with debt	93,576	1,403,546
Common stock issued in lieu of cash for dividend	386,300	184,274
Preferred stock dividends	1,727,275	1,658,175
Conversion of preferred stock for common stock	44
Conversion of debt and interest into common stock	467,092	2,989,990
Discount due to beneficial conversion feature		1,320,331
Deemed dividend - beneficial conversion feature		873,798
Conversion of debt for Series AA preferred stock		500,250
Recognition of right of use asset and liability		$ 239,327

Business Overview

Business Overview	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Overview	(1) Business Overview Pressure Biosciences, Inc. (“we”, “our”, “the Company”) develops and sells innovative, broadly enabling, high pressure-based platform technologies and related consumables for the worldwide life sciences, agriculture, food and beverage, and other key industries. Our solutions are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Historically, our primary focus has been in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. In more recent years, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. On February 8, 2021, PBI announced plans to acquire the assets of a global eco-friendly agrochemical supplier. On April 14, 2021, PBI finalized terms and executed a new letter of intent to purchase the assets of the agrochemical supplier. This opportunity is attractive as it has the potential of readily producing significant revenue, as well as the potential to apply the UST technology to improve some of the product line. In July 2021, a newly formed subsidiary of PBI, PBI Agrochem, leased a warehouse in Carson City, NV, and hired a warehouse manager.

Going Concern

Going Concern	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	(2) Going Concern We have experienced negative cash flows from operations since our inception. As of December 31, 2022, we did not have adequate working capital resources to satisfy our current liabilities and as a result we have substantial doubt about our ability to continue as a going concern.. We have been successful in raising debt and equity capital in the past and as described in Notes 9 and 10. In addition, we raised debt and equity capital after December 31, 2022 as described in Note 11. We have financing efforts in place to continue to raise cash through debt and equity offerings. Although we have successfully completed financings and reduced expenses in the past, we cannot assure you that our plans to address these matters in the future will be successful. These financial statements do not include any adjustments that might result from this uncertainty. The conditions described above could adversely affect our ability to obtain additional financing on favorable terms, if at all, and may cause investors to have reservations about our long-term prospects and may adversely affect our relationships with customers. If we cannot successfully continue as a going concern, our stockholders may lose their entire investment.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	(3) Summary of Significant Accounting Policies i. Principles of Consolidation The consolidated financial statements include the accounts of Pressure BioSciences, Inc., and its wholly owned subsidiaries PBI BioSeq, Inc and PBI Agrochem, Inc. All intercompany accounts and transactions have been eliminated in consolidation. ii. Use of Estimates To prepare our consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, we are required to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In addition, significant estimates were made in deferred tax assets, the costs associated with fulfilling our warranty obligations for the instruments that we sell, and the estimates employed in our calculation of fair value of stock options awarded. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from the estimates and assumptions used. iii Recent Accounting Pronouncement In June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments. The standard is effective for the Company for interim and annual periods beginning after December 15, 2022. The Company is evaluating the impact of this standard on its Consolidated Financial Statements. In August 2020, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, as part of its overall simplification initiative to reduce costs and complexity of applying accounting standards while maintaining or improving the usefulness of the information provided to users of financial statements. Among other changes, the new guidance removes the beneficial conversion separation model for convertible debt. As a result, after adopting the guidance, entities will no longer account for beneficial conversion features in equity. The guidance is effective for public business entities, other than small reporting company’s financial statements starting January 1, 2022, with early adoption permitted. The Company is a small reporting company and early adopted the new guidance on January 1, 2022 using the modified retrospective approach and recorded a cumulative effect of adoption equal to a $ 2,728,243 2,255,216 473,027 iv. Revenue Recognition We recognize revenue in accordance with FASB ASC 606, Revenue from Contracts with Customers, ASC 340-40, Other Assets and Deferred Costs—Contracts with Customers We identify a performance obligation as distinct if both the following criteria are true: the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract. Determining the standalone selling price (“SSP”) and allocation of consideration from a contract to the individual performance obligations, and the appropriate timing of revenue recognition, is the result of significant qualitative and quantitative judgments. Management considers a variety of factors such as historical sales, usage rates, costs, and expected margin, which may vary over time depending upon the unique facts and circumstances related to each performance obligation in making these estimates. While changes in the allocation of the SSP between performance obligations will not affect the amount of total revenue recognized for a particular contract, any material changes could impact the timing of revenue recognition, which would have a material effect on our financial position and result of operations. This is because the contract consideration is allocated to each performance obligation, delivered or undelivered, at the inception of the contract based on the SSP of each distinct performance obligation. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are in included in cost of revenues as consistent with treatment in prior periods. Our current Barocycler instruments require a basic level of instrumentation expertise to set-up for initial operation. To support a favorable first experience for our customers, upon customer request, and for an additional fee, we will send a highly trained technical representative to the customer site to install Barocyclers that we sell, lease, or rent through our domestic sales force. The installation process includes uncrating and setting up the instrument, followed by introductory user training. Our sales arrangements do not provide our customers with a right of return. Any shipping costs billed to customers are recognized as revenue. Most of our instrument and consumable contracts contain pricing that is based on the market price for the product at the time of delivery. Our obligations to deliver product volumes are typically satisfied and revenue is recognized when control of the product transfers to our customers. Concurrent with the transfer of control, we typically receive the right to payment for the shipped product and the customer has significant risks and rewards of ownership of the product. Payment terms require customers to pay shortly after delivery and do not contain significant financing components. Revenue from scientific services customers is recognized upon completion of each stage of service as defined in service agreements. We apply ASC 845, “Accounting for Non-Monetary Transactions”, to account for products and services sold through non-cash transactions based on the fair values of the products and services involved, where such values can be determined. Non-cash exchanges would require revenue to be recognized at recorded cost or carrying value of the assets or services sold if any of the following conditions apply: a) The fair value of the asset or service involved is not determinable. b) The transaction is an exchange of a product or property held for sale in the ordinary course of business for a product or property to be sold in the same line of business to facilitate sales to customers other than the parties to the exchange. c) The transaction lacks commercial substance. We recognize revenue for non-cash transactions at recorded cost or carrying value of the assets or services sold. We account for lease agreements of our instruments in accordance with ASC 842, Leases. We record revenue over the life of the lease term and we record depreciation expense on a straight-line basis over the thirty-six-month estimated useful life of the Barocycler instrument. The depreciation expense associated with assets under lease agreement is included in the “Cost of PCT products and services” line item in our accompanying consolidated statements of operations. Many of our lease and rental agreements allow the lessee to purchase the instrument at any point during the term of the agreement with partial or full credit for payments previously made. We pay all maintenance costs associated with the instrument during the term of the leases. Revenue from government grants is recorded when expenses are incurred under the grant in accordance with the terms of the grant award. Deferred revenue represents amounts received from grants and service contracts for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. Revenue from service contracts is recorded ratably over the length of the contract. Disaggregation of revenue In the following table, revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition. Schedule of Disaggregation of Revenue In thousands of US dollars ($) Year Ended December 31, Primary geographical markets 2022 2021 North America 1,191 1,179 Europe 144 289 Asia 394 534 1,729 2,002 In thousands of US dollars ($) Year Ended December 31, Major products/services lines 2022 2021 Hardware 761 1,104 Consumables 257 274 Contract research services 196 268 Agrochem Products 165 29 Sample preparation accessories 132 140 Technical support/extended service contracts 174 119 Shipping and handling 42 51 Other 2 17 1,729 2,002 In thousands of US dollars ($) Year Ended December 31, Timing of revenue recognition 2022 2021 Transferred at a point in time 1,359 1,674 Transferred over time 370 328 1,729 2,002 Contract balances Schedule of Contract Balances In thousands of US dollars ($) December 31, 2022 December 31, 2021 Receivables, which are included in ‘Accounts Receivable’ 295 155 Contract liabilities (deferred revenue) 60 41 Transaction price allocated to the remaining performance obligations The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. Schedule of Future Related to Performance Obligations In thousands of US dollars ($) 2023 2024 Total Extended warranty service 58 2 60 All consideration from contracts with customers is included in the amounts presented above. Contract Costs The Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. These costs are included in selling, general, and administrative expenses. The costs to obtain a contract are recorded immediately in the period when the revenue is recognized either upon shipment or installation. The costs to obtain a service contract are considered immaterial when spread over the life of the contract so the Company records the costs immediately upon billing. v. Beneficial Conversion Features In accordance with FASB ASC 470-20, “Debt with Conversion and Other Options” the Company records a beneficial conversion feature (“BCF”) related to the issuance of convertible debt or preferred stock instruments that have conversion features at fixed rates that are in-the-money when issued. The BCF for the convertible instruments is recognized and measured by allocating a portion of the proceeds equal to the intrinsic value of that feature to additional paid-in capital. The intrinsic value is generally calculated at the commitment date as the difference between the conversion price and the fair value of the common stock or other securities into which the security is convertible, multiplied by the number of shares into which the security is convertible. If certain other securities are issued with the convertible security, the proceeds are allocated among the different components. The portion of the proceeds allocated to the convertible security is divided by the contractual number of the conversion shares to determine the effective conversion price, which is used to measure the BCF. The effective conversion price is used to compute the intrinsic value. The value of the BCF is limited to the basis that is initially allocated to the convertible security. vi. Cash and Cash Equivalents Our policy is to invest available cash in short-term, investment grade interest-bearing obligations, including money market funds, and bank and corporate debt instruments. Securities purchased with initial maturities of three months or less are valued at cost plus accrued interest, which approximates fair value, and are classified as cash equivalents. vii. Research and Development Research and development costs, which are comprised of costs incurred in performing research and development activities including wages and associated employee benefits, facilities, consumable products and overhead costs that are expensed as incurred. In support of our research and development activities we utilize our Barocycler instruments that are capitalized as fixed assets and depreciated over their expected useful life. viii. Inventories Inventories are valued at the lower of cost (average cost) or net realizable value. The cost of Barocyclers consists of the cost charged by the contract manufacturer. The cost of manufactured goods includes material, freight-in, direct labor, and applicable overhead. The composition of inventory as of December 31, is as follows: Schedule of Inventories 2022 2021 Raw materials $ 188,587 $ 296,892 Finished goods 1,480,769 1,193,158 Inventory reserve (982,973 ) (342,496 ) Total $ 686,383 $ 1,147,554 ix. Property and Equipment Property and equipment are stated at cost, less accumulated depreciation. For financial reporting purposes, depreciation is recognized using the straight-line method, allocating the cost of the assets over their estimated useful lives of three years for certain laboratory equipment, from three to five years for management information systems and office equipment, and three years for all PCT finished units classified as fixed assets. x. Intangible Assets We have classified as intangible assets, costs associated with the fair value of acquired intellectual property. Intangible assets, including patents, are being amortized on a straight-line basis over nine years. We perform an annual review of our intangible assets for impairment. We capitalize any costs to renew or extend the term of our intangible assets. When impairment is indicated, any excess of carrying value over fair value is recorded as a loss. As of December 31, 2022, and 2021, the outstanding balance for intangible assets was $ 317,308 403,846 xi. Long-Lived Assets The Company’s long-lived assets are reviewed for impairment in accordance with the guidance of the FASB ASC 360-10-05, Property, Plant, and Equipment xii. Concentrations Credit Risk Our financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents and trade receivables. We have cash investment policies which, among other things, limit investments to investment-grade securities. We perform ongoing credit evaluations of our customers, and the risk with respect to trade receivables is further mitigated by the fact that many of our customers are government institutions and university labs. Allowances are provided for estimated amounts of accounts receivable which may not be collected. At December 31, 2022, we determined that no allowance against accounts receivable was necessary. The following table illustrates the level of concentration of the below two groups within revenue as a percentage of total revenues during the years ended December 31: Schedule of Customer Concentration Risk Percentage 2022 2021 Top Five Customers 24 % 44 % Federal Agencies 0 % 6 % The following table illustrates the level of concentration of the below two groups within accounts receivable as a percentage of total accounts receivable balance as of December 31: 2022 2021 Top Five Customers 93 % 82 % Federal Agencies 0 % 5 % Investment in Equity Securities As of December 31, 2022, we held 100,250 We had exchanged 33,334 100,250 As of December 31, 2022, our consolidated balance sheet reflected the fair value, determined on a recurring basis based on Level 1 inputs, of our investment in Nexity to be $ 63,638 3,662 As of December 31, 2021, our consolidated balance sheet reflected the fair value, determined on a recurring basis based on Level 1 inputs, of our investment in Nexity to be $ 59,976 457,025 xiii. Computation of Loss per Share Basic loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding. Diluted loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding plus additional common shares that would have been outstanding if dilutive potential common shares had been issued. For purposes of this calculation, convertible preferred stock, common stock dividends, warrants to acquire preferred stock convertible into common stock, and warrants and options to acquire common stock, are all considered common stock equivalents in periods in which they have a dilutive effect and are excluded from this calculation in periods in which these are anti-dilutive. The following table illustrates our computation of loss per share for the years ended December 31: Schedule of Computation of Loss Per Share 2022 2021 Numerator: Net loss attributable to common shareholders $ (17,803,953 ) $ (22,685,459 ) Denominator for basic and diluted loss per share: Weighted average common shares outstanding 11,058,356 6,636,523 Loss per common share - basic and diluted $ (1.61 ) $ (3.42 ) The following table presents securities that could potentially dilute basic loss per share in the future. For all periods presented, the potentially dilutive securities were not included in the computation of diluted loss per share because these securities would have been anti-dilutive for the years ended December 31: Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share 2022 2021 Stock options 1,307,822 1,333,101 Convertible debt 6,915,754 5,232,118 Common stock warrants 16,278,769 16,207,108 Convertible preferred stock: Series D Convertible Preferred 25,000 25,000 Series G Convertible Preferred 26,857 26,857 Series H Convertible Preferred 33,334 33,334 Series H2 Convertible Preferred 70,000 70,000 Series J Convertible Preferred 115,267 115,267 Series K Convertible Preferred 229,334 229,334 Series AA Convertible Preferred 8,645,000 8,649,000 Total potentially dilutive shares 33,647,137 31,921,119 xiv. Accounting for Income Taxes We account for income taxes under the asset and liability method, which requires recognition of deferred tax assets, subject to valuation allowances, and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and income tax purposes. The Company considers many factors when assessing the likelihood of future realization of our deferred tax assets, including recent cumulative earnings experience by taxing jurisdiction, expectations of future taxable income or loss, the carry-forward periods available to us for tax reporting purposes, and other relevant factors. A valuation allowance is established if it is more likely than not that all or a portion of the net deferred tax assets will not be realized. If substantial changes in the Company’s ownership should occur, as defined in Section 382 of the Internal Revenue Code, there could be significant limitations on the amount of net loss carry forwards that could be used to offset future taxable income. Tax positions must meet a “more likely than not” recognition threshold at the effective date to be recognized. At December 31, 2022 and 2021, the Company did not have any uncertain tax positions. No interest and penalties related to uncertain tax positions were accrued on December 31, 2022 and 2021. xv. Accounting for Stock-Based Compensation We maintain equity compensation plans under which incentive stock options and non-qualified stock options are granted to employees, independent members of our Board of Directors and outside consultants. We recognize equity compensation expense over the requisite service period using the Black-Scholes formula to estimate the fair value of the stock options on the date of grant. Employee and non-employee awards are accounted for under ASC 718 where the awards are valued at grant date. Determining Fair Value of Stock Option Grants Valuation and Amortization Method Expected Term Compensation-Stock Compensation Expected Volatility Risk-Free Interest Rate Forfeitures Compensation-Stock Compensation The following table summarizes the assumptions we utilized for grants of stock options to the three sub-groups of our stock option recipients during the year ended December 31, 2021 (there were no options granted in 2022): Summary of Assumptions for Grants of Stock Options Assumptions CEO, other Officers and Employees Expected life 6.0 (yrs) Expected volatility 155.02 % Risk-free interest rate 0.62 % Forfeiture rate 5.00 % Expected dividend yield 0.0 % We recognized stock-based compensation expense of $ 215,098 254,615 Schedule of Stock Based Compensation Expense 2022 2021 Research and development $ 79,891 $ 128,094 Selling and marketing 24,687 22,233 General and administrative 110,520 104,288 Total stock-based compensation expense $ 215,098 $ 254,615 During the years ended December 31, 2022 and December 31, 2021, the total fair value of stock options awarded was $ 0 49,135 As of December 31, 2022, total unrecognized compensation cost related to the unvested stock-based awards was $ 15,312 1.09 As of December 31, 2021, total unrecognized compensation cost related to the unvested stock-based awards was $ 140,455 1.09 xvi. Advertising Advertising costs are expensed as incurred. We incurred $ 487 17,594 xvii. Fair Value of Financial Instruments Due to their short maturities, the carrying amounts for cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and debt approximate their fair value. The carrying amount of long-term debt approximates fair value due to interest rates that approximate prevailing market rates. xviii. Fair Value Measurements The Company follows the guidance of FASB ASC Topic 820, “ Fair Value Measurements and Disclosures ASC 820 The Company generally defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company uses a three-tier fair value hierarchy, which classifies the inputs used in measuring fair values. These tiers include: Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company has determined that its financial assets are currently classified within Level 1. The Company does not have any financial liabilities that are required to be measured on a recurring basis at December 31, 2022 and 2021. The following tables set forth the Company’s financial assets that were accounted for at fair value on a recurring basis as of December 31, 2022: Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis Fair value measurements at December 31, 2022 using: December 31, 2022 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Equity Securities 63,638 63,638 - - Total Financial Assets $ 63,638 $ 63,638 $ - $ - The following tables set forth the Company’s financial assets that were accounted for at fair value on a recurring basis as of December 31, 2021: Fair value measurements at December 31, 2021 using: December 31, 2021 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Equity Securities $ 59,976 $ 59,976 - - Total Financial Assets $ 59,976 $ 59,976 $ - $ -

Property and Equipment, net

Property and Equipment, net	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment, net	(4) Property and Equipment, net Property and equipment as of December 31, 2022 and 2021 consisted of the following components: Schedule of Property and Equipment 2022 2021 December 31, 2022 2021 Laboratory and manufacturing equipment $ 374,132 $ 353,379 Office equipment 194,999 194,999 Leasehold improvements 25,248 25,248 PCT collaboration, demonstration and leased systems 53,098 53,098 Total property and equipment 647,477 626,724 Less accumulated depreciation (544,126 ) (510,878 ) Net book value $ 103,351 $ 115,846 Depreciation expense for the years ended December 31, 2022 and 2021 was $ 33,250 23,589

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	(5) Intangible Assets Intangible assets as of December 31, 2022 reflect the purchase price attributable to patents received in connection with the acquisition of assets of BaroFold Corp. Acquired BaroFold patents are being amortized to expense on a straight line basis at the rate of $ 80,000 9 80,000 Schedule of Intangible Assets 2022 2021 December 31, 2022 2021 BaroFold Patents $ 750,000 $ 750,000 Less accumulated amortization (432,692 ) (346,154 ) Net book value $ 317,308 $ 403,846 Amortization expense for each of the years ended December 31, 2022 and 2021 was $ 86,538

Retirement Plan

Retirement Plan	12 Months Ended
	Dec. 31, 2022
Retirement Benefits [Abstract]
Retirement Plan	(6) Retirement Plan We provide all our employees with the opportunity to participate in our retirement savings plan. Our retirement savings plan has been qualified under Section 401(k) of the Internal Revenue Code. Eligible employees are permitted to contribute to the plan through payroll deductions within statutory limitations and subject to any limitations included in the plan. During 2022 and 2021 we contributed $ 12,777 11,752

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	(7) Income Taxes Tax positions must meet a “more likely than not” recognition threshold at the effective date to be recognized. At December 31, 2022 and 2021, the Company did not have any uncertain tax positions. No Significant items making up the deferred tax assets and deferred tax liabilities as of December 31, 2022 and 2021 are as follows: Schedule of Deferred Tax Assets and Deferred Tax Liabilities 2022 2021 Long term deferred taxes: Inventory reserve $ 268,548 $ 93,570 Other accruals 99,362 91,792 Other 15,715 15,169 Non-cash, stock-based compensation, nonqualified 872,967 814,202 Impairment loss on investment 104,609 104,609 Operating loss carry forwards and tax credits 31,026,899 28,435,535 Less: valuation allowance (32,388,100 ) (29,554,877 ) Total net deferred tax assets $ - $ - A valuation allowance is established if it is more likely than not that all or a portion of the deferred tax asset will not be realized. Accordingly, we established a valuation allowance in 2022 and 2021 for the full amount of our deferred tax assets for the uncertainty of realization. We believe that based on our projection of future taxable operating income for the foreseeable future, it is more likely than not that we will not be able to realize the benefit of the deferred tax asset at December 31, 2022. We have net operating loss carry-forwards for federal income tax purposes of approximately $ 110,385,351 2023 through 2037 Under the Tax Reform Act, NOL’s generated after December 31, 2017 can offset only 80% of a corporation’s taxable income in any year. 70,711,859 We have net operating loss carry-forwards for state income tax purposes of approximately $ 106,651,967 We have research and development tax credit carryforwards for federal income tax purposes of approximately $ 1,338,308 356,424 2022 through 2037 2023 through 2034 The following table reconciles the U.S. Federal statutory tax rate to the Company’s effective tax rate: Schedule of U.S. Federal Statutory Tax Rate to Effective Income Tax Rate 2022 2021 Statutory U.S. Federal tax rate 21 % 21 % Permanent differences (0 ) (0 ) State tax expense (0 ) (0 ) Refundable AMT and R&D tax credit (0 ) (0 ) Valuation allowance (21 ) (21 ) Effective tax rate 0 % 0 %

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	(8) Commitments and Contingencies Operating Leases The Company accounts for its leases under ASC 842. The Company has elected to apply the short-term lease exception to leases of one year or less. Our corporate office is currently located at 14 Norfolk Avenue, South Easton, Massachusetts 02375. We are currently paying $ 7,650 December 31, 2023 We extended our lease for our space in Medford, MA (the “Medford Lease”) from December 30, 2020 to December 30, 2023. The lease required monthly payments of $ 7,282 The lease shall be automatically extended for additional three years unless either party terminates at least six months prior to the expiration of the current lease term. The Company accounted for the lease extension of our Medford Lease as a lease modification under ASC 842. At the effective date of modification, the Company recorded an adjustment to the right-of-use asset and lease liability in the amount of $ 221,432 12 On August 9, 2021, we entered into an operating lease agreement for our warehouse space in Sparks, NV (the “Sparks Lease”) for the period from September 1, 2021 through September 30, 2026. The lease contains escalating payments during the lease period. The lease can be extended for an additional three years if the Company provides notice at least six months prior to the expiration of the current lease term. The Company accounted for the Sparks Lease as an operating lease under ASC 842. Upon the commencement of the lease, the Company recorded a right-of-use asset and lease liability in the amount of $ 239,327 12 Following is a schedule by years of future minimum rental payments required under operating leases with initial or remaining non-cancelable lease terms for greater than one year as of December 31, 2022: Schedule of Future Minimum Rental Payments Required Under Operating Leases 2023 $ 149,300 2024 64,393 2025 66,969 2026 51,778 2027 - Thereafter - Total future undiscounted lease payments $ 332,440 Less imputed interest (50,345 ) Present value of lease liabilities $ 282,095 The operating cash flows from the operating leases were $ 113,470 65,194 Below is a table for the right of use asset and the corresponding lease liability in the consolidated balance sheets: Schedule Of Right Of Use Asset And The Corresponding Lease Liability Operating Leases December 31, 2022 December 31, 2021 Right of use asset $ 282,095 $ 395,565 Right of use lease liability, current $ 142,171 $ 132,996 Right of use lease liability, long term $ 139,924 $ 262,569 Total lease liability $ 282,095 $ 395,565 The weighted-average remaining lease term (years) of the above leases is 2.96 3.7 12 The Company had no The components of lease cost for operating leases for the years ended December 31, 2022 and 2021 are as follows: Schedule of Lease Cost for Operating Leases December 31, 2022 December 31, 2021 Operating lease cost $ 151,239 $ 87,383 Short-term lease cost 91,800 91,800 Total lease cost $ 243,039 $ 179,183 Battelle Memorial Institute In December 2008, we entered into an exclusive patent license agreement with the Battelle Memorial Institute (“ Battelle 1,200 2,000 3,000 4,000 5,000 Target Discovery Inc . In March 2010, we signed a strategic product licensing, manufacturing, co-marketing, and collaborative research and development agreement with Target Discovery Inc. (“TDI”), a related party. Under the terms of the agreement, we have been licensed by TDI to manufacture and sell a highly innovative line of chemicals used in the preparation of tissues for scientific analysis (“TDI reagents”). The TDI reagents were designed for use in combination with our pressure cycling technology. The companies believe that the combination of PCT and the TDI reagents can fill an existing need in life science research for an automated method for rapid extraction and recovery of intact, functional proteins associated with cell membranes in tissue samples. We did not incur any royalty obligation under this agreement in 2022 or 2021. In April 2012, we signed a non-exclusive license agreement with TDI to grant the non-exclusive use of our pressure cycling technology. We executed an amendment to this agreement on October 1, 2016 wherein we agreed to pay a monthly fee of $ 1,400 2,000 60,000 60,000 69,300 82,800 Severance and Change of Control Agreements Each of Mr. Schumacher, and Drs. Ting, and Lazarev, executive officers of the Company, are entitled to receive a severance payment if terminated by us without cause. The severance benefits would include a payment in an amount equal to one year of such executive officer’s annualized base salary compensation plus accrued paid time off. Additionally, the officer will be entitled to receive medical and dental insurance coverage for one year following the date of termination. Each of these executive officers, other than Mr. Schumacher, is entitled to receive a change of control payment in an amount equal to one year of such executive officer’s annualized base salary compensation, accrued paid time off, and medical and dental coverage, in the event of their termination upon a change of control of the Company. In the case of Mr. Schumacher, this payment would be equal to two years of annualized base salary compensation, accrued paid time off, and two years of medical and dental coverage. The severance payment is meant to induce the aforementioned executives to remain in the employ of the Company, in general, and particularly in the occurrence of a change in control, as a disincentive to the control change.

Debt

Debt	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Debt	(9) Debt Convertible Debt On various dates during the year ended December 31, 2022, the Company issued convertible notes for net proceeds of approximately $ 4.9 million which contained varied terms and conditions as follows: a) 1 - 12 month maturity date; b) interest rates of 0 - 18 % per annum c) convertible to the Company’s common stock at issuance at a fixed rate of $ 2.50 or at variable conversion rates upon the Company’s up-listing to NASDAQ or NYSE or an event of default. These notes were issued with shares of common stock or warrants to purchase common stock that were fairly valued at issuance dates. The aggregate relative fair value of the shares of common stock issued with the notes of $ 873,854 was recorded as a debt discount to be amortized over the term of the notes. The aggregate relative fair value of the warrants issued with the notes of $ 93,576 541,313 1,522,494 1,694,028. On various dates during the year ended December 31, 2021, the Company issued convertible notes for net proceeds of approximately $ 5.5 6 12 10 18 2.50 3.00 646,718 1.4 1.3 6.7 The summary of specific terms of the convertible notes and outstanding balances as of December 31, 2022 and December 31, 2021 are listed in the tables below. The convertible notes are from numerous parties and with original issue dates from June, 2019 to December, 2022, and maturity dates from March, 2020 to December, 2023 12 Schedule of Convertible Debts and Outstanding Balances December 31, 2022 December 31, 2021 Holders Interest Rate Conversion Price Principal Interest Rate Conversion Price Principal Main Investor 10 % $ 2.50 (1) $ 9,393,150 10 % $ 2.50 (1) $ 9,393,150 Others 0 24 % $ 2.50 7.50 (2) 8,886,036 1 24 % $ 2.50 (2) 4,983,312 Totals 18,279,186 14,376,462 Discount 455,517 1,536,649 Net $ 17,823,669 $ 12,839,813 Notes: (1) Conversion price of these note is $ 2.50 189,750 25 (2) Conversion price of these notes is $ 2.50 a. Notes are convertible before maturity at $ 2.50 2.50 b. Notes are convertible upon an Event of Default at 75 c. Notes are convertible at $ 2.50 75 d. Notes can be voluntary converted at lower of 1) $ 2.50 2.50 2.50 30 e. Notes can be voluntary converted at lower of 1) $ 2.50 2.50 2.50 25 f. Conversion price is lower of (i) $ 2.50 g. Note can be converted at a Voluntary Conversion Price which is the lower of 1) $ 2.50 2.50 70 h. Conversion price is $ 2.50 1 i. Notes can be voluntarily converted before maturity at $ 2.50 2.50 10 j. Notes can be converted at the lesser of $ 2.5 25 35 k. Some notes are not convertible until 180 days from the date of issuance of the Note and following an Event of Default will be convertible at the lowest trading price of the 20 days prior to conversion. The loan with a principal balance of $ 700,000 l. Some notes can be converted at the lesser of $ 2.50 25 5 m. Some notes are not convertible until 180 days from the date of issuance of the Note and following an Event of Default will be convertible at the lesser of $ 2.50 90 n. Some notes are convertible, upon an event of default, at the lowest closing bid price for the Company’s common stock for the five trading days prior to conversion. As of December 31, 2022, the approximate principal balance that are secured by the assets of the Company’s subsidiary, PBI Agrochem, Inc. is $ 352,188 During the year ended December 31, 2022, the Company extended 11 loans totaling $ 1,815,000 3,024,561 1,423,800 Standstill and Forbearance Agreements The Company has entered into Standstill and Forbearance Agreements with lenders who hold variable-rate convertible notes with a total principal as of December 31, 2022 of $ 574,984 . Pursuant to the Standstill and Forbearance Agreements, the lenders agreed to not convert any portion of their notes into shares of common stock at a variable rate until March 31, 2021 for convertible notes with a principal balance of $ 469,000 and until April 16, 2021 for convertible notes with a principal balance of $ 1.1 million. During the year ended December 31, 2022, the Company settled one note with total principal of $ 166,703 , leaving two final lenders (four notes) with total principal of $ 574,984 outstanding and incurred interest, penalties and fees of approximately $ 0.8 827,500 1.47 Convertible Loan Modifications and Extinguishments We refinanced certain convertible loans during the years ended December 31, 2022 and 2021 at substantially the same terms for extensions ranging over a period of three to six months. We amortized any remaining unamortized debt discount as of the modification date over the remaining, extended term of the new loans. We applied ASC 470 of modification accounting to the debt instruments which were modified during the period or those settled with new notes issued concurrently for the same amounts but different maturity dates. The terms such as the interest rate, prepayment penalties, and default rates will be the same over the new extensions. According to ASC 470, an exchange of debt instruments between or a modification of a debt instrument by a debtor and a creditor in a nontroubled debt situation is deemed to have been accomplished with debt instruments that are substantially different if the present value of the cash flows under the terms of the new debt instrument is at least 10 percent different from the present value of the remaining cash flows under the terms of the original instrument. If the terms of a debt instrument are changed or modified and the cash flow effect on a present value basis is less than 10 percent, the debt instruments are not considered to be substantially different and will be accounted for as modifications. The cash flows of new debt exceeded 10 751,335 1,061,073 Other Debt On October 11, 2019 we received a non-convertible loan with a one month 2 25,000 17,000 3.50 No notes in Other Debt are past due as of December 31, 2022. Schedule of Other Debt December 31, 2022 December 31, 2021 Holders Interest Rate Principal Interest Rate Principal Non-Convertible - ) $ 878,809 - ) $ 857,930 Merchant debt (3) 760,160 388,910 SBA ( 2 3.75 % 150,000 3.75 % 160,000 Totals 1,788,969 $ 1,406,840 Long Term 150,000 150,000 Short Term $ 1,638,969 $ 1,256,840 Notes: (1) Interest varies from 1 10 May 2, 2023 861,500 (2) The Company entered into a COVID-19 government loan in 2020, the Economic Injury Disaster Loan (or “EIDL”). The Company’s EIDL loan, $ 150,000 3.75 731 367,039 1 367,039 (3) During the years ended December 31, 2022 and 2021 we signed various Merchant Agreements which are secured by second position rights to all customer receipts until the loan has been repaid in full and subject to interest rates of 4.1 14 maturity dates ranged from April 4, 2023 to June 6, 2023. maturity dates ranged from January 7 to January 11, 2022. Related Party Debt Schedule of Related Party Debt December 31, 2022 December 31, 2021 Holders Interest Rate Principal Interest Rate Principal Security Officers & Directors - ) $ 521,950 $ - Unsecured Other Related Parties 12 % 120,850 Unsecured Totals 642,800 Discount 7,915 Net $ 634,885 $ - Notes: (1) Interest varies from 12 120 During the year ended December 31, 2022, we received short-term non-convertible loans of $ 958,100 with $91,750 OID from related parties and repaid $ 315,300 of related party loans. These notes bear interest ranging from 12 % to 120 % interest and are due upon demand. During the year ended December 31, 2021, we received short-term non-convertible loans of $ 254,600 354,600 0 15 69.5 69,450 3.50 66,000 107,625 We amortized $ 83,835 49,564 7,915 0

Stockholders_ (Deficit)

Stockholders’ (Deficit)	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Stockholders’ (Deficit)	(10) Stockholders’ (Deficit) Preferred Stock We are authorized to issue 1,000,000 0.01 As of December 31, 2022 and as of December 31, 2021, there were no shares of Junior A issued and outstanding, and no Below is a summary table of the preferred stock: Schedule of Preferred Stock Outstanding December 31, 2022 December 31, 2021 Series D Convertible Preferred Stock, $ .01 850 300 300,000 $ 3 $ 3 Series G Convertible Preferred Stock, $ .01 240,000 80,570 806 806 Series H Convertible Preferred Stock, $ .01 10,000 10,000 100 100 Series J Convertible Preferred Stock, $ .01 6,250 3,458 35 35 Series K Convertible Preferred Stock, $ .01 15,000 6,880 68 68 Series AA Convertible Preferred Stock, $ .01 10,000 8,645 8,649 86 87 Series H2 Convertible Preferred Stock, $ .01 21 21 - - Series A Junior Participating Preferred Stock, $ .01 20,000 no - - Series A Convertible Preferred Stock, $ .01 313,960 no - - Series B Convertible Preferred Stock, $ .01 279,256 no - - Series C Convertible Preferred Stock, $ .01 88,098 no - - Series E Convertible Preferred Stock, $ .01 500 no - - Total Convertible Preferred Shares $ 1,098 $ 1,099 Series D Convertible Preferred Stock On November 11, 2011, we completed a registered direct offering, pursuant to which we sold an aggregate of 843 1,000 843,000 Series D Placement Series D Unit 0.01 Series D Convertible Preferred Stock 84 five 21 24.30 Series D Warrant The Series D Convertible Preferred Stock will rank senior to the Company’s common stock with respect to payments made upon liquidation, winding up or dissolution. Upon any liquidation, dissolution or winding up of the Company, after payment of the Company’s debts and liabilities, and before any payment is made to the holders of any junior securities, the holders of Series D Convertible Preferred Stock will first be entitled to be paid $ 1,000 We may not pay any dividends on shares of common stock unless we also pay dividends on the Series D Convertible Preferred Stock in the same form and amount, on an as-if-converted basis, as dividends actually paid on shares of our common stock. Except for such dividends, no other dividends may be paid on the Series D Convertible Preferred Stock. Each share of Series D Convertible Preferred Stock is convertible into 84 19.50 Series D Conversion Ratio 300 50,000 In addition, in the event we consummate a merger or consolidation with or into another person or other reorganization event in which our shares of common stock are converted or exchanged for securities, cash or other property, or we sell, lease, license or otherwise dispose of all or substantially all of our assets or we or another person acquire 50 The holders of Series D Convertible Preferred Stock are not entitled to vote on any matters presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in lieu of meeting), except that the holders of Series D Convertible Preferred Stock may vote separately as a class on any matters that would (i) amend, our Restated Articles of Organization, as amended, in a manner that adversely affects the rights of the Series D Convertible Preferred Stock, (ii) alter or change adversely the powers, preferences or rights of the Series D Convertible Preferred Stock or alter or amend the certificate of designation, (iii) authorize or create any class of shares ranking as to dividends, redemption or distribution of assets upon liquidation senior to, or otherwise pari passu with, the Series D Convertible Preferred Stock, or (iv) increase the number of authorized shares of Series D Convertible Preferred Stock. If, within 12 months of the initial issuance of the Series D Convertible Preferred Stock, we issue any common stock, common stock equivalents, indebtedness or any combination thereof (a “ Subsequent Financing the holders of Series D Convertible Preferred Stock will have the right to participate on a pro-rata basis in up to 50% of such Subsequent Financing. Series D Warrants All of these warrants have expired. Series G Convertible Preferred Stock On July 6 and November 15, 2012, we completed a private placement, pursuant to which we sold an aggregate of 4,844 150.00 726,600 Series G Private Placement Series G Unit 0.01 1 three 1 15.00 Series G Warrant Each share of Series G Preferred Stock will receive a cumulative dividend at the annual rate of (i) four percent ( 4 100,000 6 100,000 250,000 12 250,000 At the election of the Company and upon required advanced notice, each share of Series G Preferred Stock will automatically be converted into shares of common stock at the Conversion Ratio then in effect: (i) if, after 6 months from the original issuance date of the Series G Preferred Stock, the common stock trades on the OTCQB (or other primary trading market or exchange on which the common stock is then traded) at a price equal to at least $ 22.50 334 22.50 2.5 The holders of Series G Preferred Stock are not entitled to vote on any matters presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in lieu of meeting), except as required by law. Series H Convertible Preferred Stock On December 28, 2012 the Company amended the Articles of Incorporation to authorize 10,000 33,334 0.01 10,000 0.01 Series H Preferred Stock 24.08 4 24.08 Series H2 Convertible Preferred Stock On December 23, 2014 the Company amended the Articles of Incorporation to authorize 21 70,000 0.01 21 0.01 Series H2 Preferred Stock 7.50 3,334 7.50 Series J Convertible Preferred Stock On February 6, March 28 and May 20, 2013, the Company entered into a Securities Purchase with various individuals pursuant to which the Company sold an aggregate of 5,087.5 400.00 2,034,700 0.01 34 0.01 12.00 From the date of issuance of any shares of Series J Convertible Preferred Stock and until the earlier of the first anniversary of such date, the voluntary conversion of any shares of Series J Convertible Preferred Stock, or the date of any mandatory conversion (solely under the Company’s control based upon certain triggering events) of the Series J Convertible Preferred Stock, dividends will accrue on each share of Series J Convertible Preferred Stock at an annual rate of (i) four percent ( 4 50,000 6 250,000 Each share of Series J Convertible Preferred Stock is convertible into 34 At the election of the Company and upon required advance notice, each share of Series J Convertible Preferred Stock will automatically be converted into shares of common stock at the Conversion Ratio then in effect: (i) on or after the six-month anniversary of the original issuance date of the Series J Convertible Preferred Stock, the common stock trades on the OTCQB (or other primary trading market or exchange on which the common stock is then traded) at a price per share equal to at least $ 24.00 1,667 24.00 2.5 The holders of Series J Convertible Preferred Stock are not entitled to vote on any matters presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in lieu of meeting), except as required by law. Series K Convertible Preferred Stock From the date of issuance of any shares of Series K Convertible Preferred Stock and until the earlier of the first anniversary of such date, the voluntary conversion of any shares of Series K Convertible Preferred Stock, or the date of any mandatory conversion (solely under the Company’s control based upon certain triggering events) of the Series K Convertible Preferred Stock, dividends will accrue on each share of Series K Convertible Preferred Stock at an annual rate of (i) four percent ( 4 100,000 6 100,000 Each share of Series K Convertible Preferred Stock is convertible into 34 At the election of the Company and upon required advance notice, each share of Series K Convertible Preferred Stock will automatically be converted into shares of common stock at the Conversion Ratio then in effect: (i) on or after the six-month anniversary of the original issuance date of the Series K Convertible Preferred Stock, the common stock trades on the OTCQB (or other primary trading market or exchange on which the common stock is then traded) at a price per share equal to at least $ 24.00 1,667 24.00 2.5 The holders of Series K Convertible Preferred Stock are not entitled to vote on any matters presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in lieu of meeting), except as required by law. Series AA Convertible Preferred Stock and Warrants During the year ended December 31, 2021, the Company entered into Securities Purchase Agreements with accredited investors pursuant to which the Company sold an aggregate of 406 1,000 0.01 1,015,000 406,000 3.50 509,130 200 200,100 five 3.50 245,635 23,004 During the year ended December 31, 2022, there was 4,400 1,727,275 1,658,175 The issuances of our convertible preferred stock and common stock purchase warrants are accounted for under the fair value and relative fair value method. The warrant is first analyzed per its terms as to whether it has derivative features or not. If the warrant is determined to be a derivative, then it is measured at fair value using the Black Scholes Option Model and recorded as a liability on the balance sheet. The warrant is re-measured at its then current fair value at each subsequent reporting date (it is “marked-to-market”). If the warrant is determined to not have derivative features, it is recorded into equity at its fair value using the Black Scholes option model, however, limited to a relative fair value based upon the percentage of its fair value to the total fair value including the fair value of the convertible preferred stock. We analyzed these warrants issued in 2021 and determined that they were not considered derivatives and therefore recorded the aggregate relative fair value of $ 509,130 406,000 The convertible preferred stock is recorded at its fair value, limited to a relative fair value based upon the percentage of its fair value to the total fair value including the fair value of the warrant. Further, the convertible preferred stock is examined for any intrinsic beneficial conversion feature (“BCF”) of which the convertible price of the preferred stock is less than the closing stock price on date of issuance. If the relative fair value method is used to value the convertible preferred stock and there is an intrinsic BCF, a further analysis is undertaken of the BCF using an effective conversion price which assumes the conversion price is the relative fair value divided by the number of shares of common stock the convertible preferred stock is converted into by its terms. The adjusted BCF value of $ 0 873,798 Common Stock Stock Options and Warrants At the Company’s December 30, 2021 Special Meeting, the shareholder’s approved the 2021 Equity Incentive Plan (the “2021 Plan”) pursuant to which 3,000,000 1,307,822 All of the outstanding non-qualified options had an exercise price that was at or above the Company’s common stock share price at time of issuance. As of December 31, 2022, total unrecognized compensation cost related to the unvested stock-based awards was $ 15,312 1.09 1.30 0 1.53 As of December 31, 2021, total unrecognized compensation cost related to the unvested stock-based awards was $ 140,455 1.09 2.31 2,124,104 2.39 The following tables summarize information concerning options and warrants outstanding and exercisable: Schedule of Concerning Options and Warrants Outstanding and Exercisable Stock Options Warrants Total Shares Weighted Shares Weighted Shares Exercisable Balance outstanding, December 31, 2020 1,355,901 $ 0.71 14,434,702 $ 3.50 15,790,603 15,302,830 Granted 24,000 2.17 2,235,408 3.57 2,259,408 Exercised (21,411 ) 0.69 (187,500 ) 3.50 (208,911 ) Expired - - (275,502 ) 3.50 (275,502 ) Forfeited (25,389 ) 0.69 - - (25,389 ) Balance outstanding, December 31, 2021 1,333,101 $ 0.72 16,207,108 $ 3.50 17,540,209 17,308,567 Granted - - 277,500 3.50 277,500 Exercised (25,279 ) 0.69 - - (25,279 ) Expired - - (205,839 ) 3.50 (205,839 ) Forfeited - - - - - Balance outstanding, December 31, 2022 1,307,822 $ 0.72 16,278,769 $ 3.50 17,586,591 17,570,591 Schedule of Share-based Compensation Stock Option Plans by Exercise Price Range Options Outstanding Options Exercisable Weighted Average Weighted Average Range of Number of Remaining Exercise Number of Remaining Exercise $ 0.69 $ 1.00 1,283,822 6.7 $ 0.69 1,283,822 6.7 $ 0.69 $ 1.01 $ 3.00 24,000 8.1 $ 2.17 8,000 8.1 $ 2.17 1,307,822 6.7 $ 0.72 1,291,822 6.7 $ 0.69 Common Stock Issuances For the year ended December 31, 2022 the Company recognized 25,279 17,443 255,500 392,175 1,423,800 2,198,861 181,918 467,092 4,400 236,221 386,300 1,766,266 2,943,139 659,000 873,854 10,000 25,000 On various dates in the year ended December 31, 2021 the Company issued 333,200 shares with a fair value of $ 794,562 for services rendered; 36,290 shares for a cashless warrant exercise; 82,373 shares with a fair value of $ 184,274 in lieu of cash for the 8 % dividend on Series AA Convertible Preferred Stock; 1,195,996 shares with a fair value of $ 2,989,990 for the conversion of debt and interest for common stock; 2,883,282 shares with a fair value of $ 6,665,656 for debt extension, settlement and interest payments, 21,411 shares for stock option exercises (at an exercise price of $ 0.69 ) and 399,650 shares with a fair value of $ 646,718 in conjunction with the signing of new convertible loans. During this period, we also issued 1,146,945 warrants ( three to five -year term at a $ 3.50 to $ 5.00 exercise price) to acquire common stock at a fair value of $ 1.4 million to lenders in conjunction with signing of new convertible loans. We also issued 71,042 warrants ( 3 -year term at $ 3.5 exercise price) to acquire common stock at a fair value of $ 107,275 to lender in for debt settlement. As profiled in the following table, for seven loans we are obligated to issue common stock if not paid by defined dates. Schedule of Loans Obligated to Issue Shares Loan Issuance Loan Percentage of Loan Principal Defined Shares Issuable Loan Date Principal Issuable Date Frequency Loan 1(1) July 21, 2020 $ 115,000 0.0435 % September 30, 2020 Monthly Loan 2 September 21, 2020 $ 345,000 0.0362 % November 16, 2020 Weekly Loan 5 October 22, 2020 $ 115,000 0.0652 % December 1, 2020 Weekly Loan 6 October 21, 2021 $ 189,750 0.0435 % January 2, 2022 Monthly Loan 7 November 1, 2021 $ 189,750 0.0435 % January 2, 2022 Monthly Notes: (1) Per second amendment, if the note is not fully paid by 12/16/22, the holder shall receive 8,250 8,250 During the year ended December 31, 2022, the Company accrued approximately $ 2.7 6,288,529 For our loan dated December 23, 2020, we are obligated to issue 100,000 warrants if the loan is not repaid before January 23, 2021 and an additional 10,000 shares of common stock and 100,000 warrants if the loan is not repaid before February 23, 2021. We are also obligated to issue 10,000 shares of common stock and 200,000 warrants if the loan is not repaid before March 23, 2021. During the year ended December 31, 2021 the Company issued 400,000 3.50 600,298 10,000 For the twelve months ended December 31, 2022, the Company issued a total of 277,500 280,608 3.50 3 5 ● 120,000 93,576 ● 100,000 132,537 ● 57,500 54,496 For the twelve months ended December 31, 2021, the company also issued 2,235,408 three five 3.50 5.00 2.4

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	(11) Subsequent Events On January 18, 2023, the Company’s board of directors in accordance with the recommendations of the Company’s approved the issuance of 1,530,944 699,540 1.50 All directors’ stock options vested 100 25 75 On February 28, 2023, the Company entered into a Securities Issuance and Exchange Agreement (the “Issuance and Exchange Agreement”) with an accredited investor (the “Investor”) whereby the Investor agreed to accept shares of a series of the Company’s preferred stock in exchange for three categories of cash amounts owed to the Investor. The series of preferred stock has not yet been created; however, each share of the newly created preferred stock will have a value of $ 25,000 2.50 0.01 10,000 The Investor agreed to accept shares of preferred stock in exchange for (i) $ 6,226,125 2,255,587 9,393,150 1,535,500 9.39 The $ 10,017,212 400.6885 400.6885 4,000,000 On February 28, 2023, the Company received an executed Notice of Conversion from an accredited investor (the “Investor”) who elected to convert 101,154 493,540 From January 1, 2023, through March 31, 2023, the Company issued ten (10) convertible loans for approximately $2,900,000, which each carry a 10-40% annual interest rate and four (4) to twelve (12) month terms and convertible to the Company’s common stock at a $2.50 conversion price. The Company issued 618,150 common stock and 325,000 preferred stock along with the loan issuance. In this period, the Company also borrowed $55,000 from related parties with 10% original issue discount and 10% per month interest rate and entered into seven (7) new Merchant Cash lender agreements with an original total outstanding balance of $1,498,769 and obligated the Company to pay $60,157 each week to the lenders. In this time the Company also repaid one loan totaling $ 460,000 January 3, 2023 26,000 March 1, 2023 2,500 During this period the Company also issued 203,613 509,032 302,482 206,050 500 40,000 2.50 884,000 100,000 3.50

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Principles of Consolidation	i. Principles of Consolidation The consolidated financial statements include the accounts of Pressure BioSciences, Inc., and its wholly owned subsidiaries PBI BioSeq, Inc and PBI Agrochem, Inc. All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	ii. Use of Estimates To prepare our consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, we are required to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In addition, significant estimates were made in deferred tax assets, the costs associated with fulfilling our warranty obligations for the instruments that we sell, and the estimates employed in our calculation of fair value of stock options awarded. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from the estimates and assumptions used.
Recent Accounting Pronouncement	iii Recent Accounting Pronouncement In June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments. The standard is effective for the Company for interim and annual periods beginning after December 15, 2022. The Company is evaluating the impact of this standard on its Consolidated Financial Statements. In August 2020, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, as part of its overall simplification initiative to reduce costs and complexity of applying accounting standards while maintaining or improving the usefulness of the information provided to users of financial statements. Among other changes, the new guidance removes the beneficial conversion separation model for convertible debt. As a result, after adopting the guidance, entities will no longer account for beneficial conversion features in equity. The guidance is effective for public business entities, other than small reporting company’s financial statements starting January 1, 2022, with early adoption permitted. The Company is a small reporting company and early adopted the new guidance on January 1, 2022 using the modified retrospective approach and recorded a cumulative effect of adoption equal to a $ 2,728,243 2,255,216 473,027
Revenue Recognition	iv. Revenue Recognition We recognize revenue in accordance with FASB ASC 606, Revenue from Contracts with Customers, ASC 340-40, Other Assets and Deferred Costs—Contracts with Customers We identify a performance obligation as distinct if both the following criteria are true: the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract. Determining the standalone selling price (“SSP”) and allocation of consideration from a contract to the individual performance obligations, and the appropriate timing of revenue recognition, is the result of significant qualitative and quantitative judgments. Management considers a variety of factors such as historical sales, usage rates, costs, and expected margin, which may vary over time depending upon the unique facts and circumstances related to each performance obligation in making these estimates. While changes in the allocation of the SSP between performance obligations will not affect the amount of total revenue recognized for a particular contract, any material changes could impact the timing of revenue recognition, which would have a material effect on our financial position and result of operations. This is because the contract consideration is allocated to each performance obligation, delivered or undelivered, at the inception of the contract based on the SSP of each distinct performance obligation. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are in included in cost of revenues as consistent with treatment in prior periods. Our current Barocycler instruments require a basic level of instrumentation expertise to set-up for initial operation. To support a favorable first experience for our customers, upon customer request, and for an additional fee, we will send a highly trained technical representative to the customer site to install Barocyclers that we sell, lease, or rent through our domestic sales force. The installation process includes uncrating and setting up the instrument, followed by introductory user training. Our sales arrangements do not provide our customers with a right of return. Any shipping costs billed to customers are recognized as revenue. Most of our instrument and consumable contracts contain pricing that is based on the market price for the product at the time of delivery. Our obligations to deliver product volumes are typically satisfied and revenue is recognized when control of the product transfers to our customers. Concurrent with the transfer of control, we typically receive the right to payment for the shipped product and the customer has significant risks and rewards of ownership of the product. Payment terms require customers to pay shortly after delivery and do not contain significant financing components. Revenue from scientific services customers is recognized upon completion of each stage of service as defined in service agreements. We apply ASC 845, “Accounting for Non-Monetary Transactions”, to account for products and services sold through non-cash transactions based on the fair values of the products and services involved, where such values can be determined. Non-cash exchanges would require revenue to be recognized at recorded cost or carrying value of the assets or services sold if any of the following conditions apply: a) The fair value of the asset or service involved is not determinable. b) The transaction is an exchange of a product or property held for sale in the ordinary course of business for a product or property to be sold in the same line of business to facilitate sales to customers other than the parties to the exchange. c) The transaction lacks commercial substance. We recognize revenue for non-cash transactions at recorded cost or carrying value of the assets or services sold. We account for lease agreements of our instruments in accordance with ASC 842, Leases. We record revenue over the life of the lease term and we record depreciation expense on a straight-line basis over the thirty-six-month estimated useful life of the Barocycler instrument. The depreciation expense associated with assets under lease agreement is included in the “Cost of PCT products and services” line item in our accompanying consolidated statements of operations. Many of our lease and rental agreements allow the lessee to purchase the instrument at any point during the term of the agreement with partial or full credit for payments previously made. We pay all maintenance costs associated with the instrument during the term of the leases. Revenue from government grants is recorded when expenses are incurred under the grant in accordance with the terms of the grant award. Deferred revenue represents amounts received from grants and service contracts for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. Revenue from service contracts is recorded ratably over the length of the contract. Disaggregation of revenue In the following table, revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition. Schedule of Disaggregation of Revenue In thousands of US dollars ($) Year Ended December 31, Primary geographical markets 2022 2021 North America 1,191 1,179 Europe 144 289 Asia 394 534 1,729 2,002 In thousands of US dollars ($) Year Ended December 31, Major products/services lines 2022 2021 Hardware 761 1,104 Consumables 257 274 Contract research services 196 268 Agrochem Products 165 29 Sample preparation accessories 132 140 Technical support/extended service contracts 174 119 Shipping and handling 42 51 Other 2 17 1,729 2,002 In thousands of US dollars ($) Year Ended December 31, Timing of revenue recognition 2022 2021 Transferred at a point in time 1,359 1,674 Transferred over time 370 328 1,729 2,002 Contract balances Schedule of Contract Balances In thousands of US dollars ($) December 31, 2022 December 31, 2021 Receivables, which are included in ‘Accounts Receivable’ 295 155 Contract liabilities (deferred revenue) 60 41 Transaction price allocated to the remaining performance obligations The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. Schedule of Future Related to Performance Obligations In thousands of US dollars ($) 2023 2024 Total Extended warranty service 58 2 60 All consideration from contracts with customers is included in the amounts presented above. Contract Costs The Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. These costs are included in selling, general, and administrative expenses. The costs to obtain a contract are recorded immediately in the period when the revenue is recognized either upon shipment or installation. The costs to obtain a service contract are considered immaterial when spread over the life of the contract so the Company records the costs immediately upon billing.
Beneficial Conversion Features	v. Beneficial Conversion Features In accordance with FASB ASC 470-20, “Debt with Conversion and Other Options” the Company records a beneficial conversion feature (“BCF”) related to the issuance of convertible debt or preferred stock instruments that have conversion features at fixed rates that are in-the-money when issued. The BCF for the convertible instruments is recognized and measured by allocating a portion of the proceeds equal to the intrinsic value of that feature to additional paid-in capital. The intrinsic value is generally calculated at the commitment date as the difference between the conversion price and the fair value of the common stock or other securities into which the security is convertible, multiplied by the number of shares into which the security is convertible. If certain other securities are issued with the convertible security, the proceeds are allocated among the different components. The portion of the proceeds allocated to the convertible security is divided by the contractual number of the conversion shares to determine the effective conversion price, which is used to measure the BCF. The effective conversion price is used to compute the intrinsic value. The value of the BCF is limited to the basis that is initially allocated to the convertible security.
Cash and Cash Equivalents	vi. Cash and Cash Equivalents Our policy is to invest available cash in short-term, investment grade interest-bearing obligations, including money market funds, and bank and corporate debt instruments. Securities purchased with initial maturities of three months or less are valued at cost plus accrued interest, which approximates fair value, and are classified as cash equivalents.
Research and Development	vii. Research and Development Research and development costs, which are comprised of costs incurred in performing research and development activities including wages and associated employee benefits, facilities, consumable products and overhead costs that are expensed as incurred. In support of our research and development activities we utilize our Barocycler instruments that are capitalized as fixed assets and depreciated over their expected useful life.
Inventories	viii. Inventories Inventories are valued at the lower of cost (average cost) or net realizable value. The cost of Barocyclers consists of the cost charged by the contract manufacturer. The cost of manufactured goods includes material, freight-in, direct labor, and applicable overhead. The composition of inventory as of December 31, is as follows: Schedule of Inventories 2022 2021 Raw materials $ 188,587 $ 296,892 Finished goods 1,480,769 1,193,158 Inventory reserve (982,973 ) (342,496 ) Total $ 686,383 $ 1,147,554
Property and Equipment	ix. Property and Equipment Property and equipment are stated at cost, less accumulated depreciation. For financial reporting purposes, depreciation is recognized using the straight-line method, allocating the cost of the assets over their estimated useful lives of three years for certain laboratory equipment, from three to five years for management information systems and office equipment, and three years for all PCT finished units classified as fixed assets.
Intangible Assets	x. Intangible Assets We have classified as intangible assets, costs associated with the fair value of acquired intellectual property. Intangible assets, including patents, are being amortized on a straight-line basis over nine years. We perform an annual review of our intangible assets for impairment. We capitalize any costs to renew or extend the term of our intangible assets. When impairment is indicated, any excess of carrying value over fair value is recorded as a loss. As of December 31, 2022, and 2021, the outstanding balance for intangible assets was $ 317,308 403,846
Long-Lived Assets	xi. Long-Lived Assets The Company’s long-lived assets are reviewed for impairment in accordance with the guidance of the FASB ASC 360-10-05, Property, Plant, and Equipment
Concentrations	xii. Concentrations Credit Risk Our financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents and trade receivables. We have cash investment policies which, among other things, limit investments to investment-grade securities. We perform ongoing credit evaluations of our customers, and the risk with respect to trade receivables is further mitigated by the fact that many of our customers are government institutions and university labs. Allowances are provided for estimated amounts of accounts receivable which may not be collected. At December 31, 2022, we determined that no allowance against accounts receivable was necessary. The following table illustrates the level of concentration of the below two groups within revenue as a percentage of total revenues during the years ended December 31: Schedule of Customer Concentration Risk Percentage 2022 2021 Top Five Customers 24 % 44 % Federal Agencies 0 % 6 % The following table illustrates the level of concentration of the below two groups within accounts receivable as a percentage of total accounts receivable balance as of December 31: 2022 2021 Top Five Customers 93 % 82 % Federal Agencies 0 % 5 % Investment in Equity Securities As of December 31, 2022, we held 100,250 We had exchanged 33,334 100,250 As of December 31, 2022, our consolidated balance sheet reflected the fair value, determined on a recurring basis based on Level 1 inputs, of our investment in Nexity to be $ 63,638 3,662 As of December 31, 2021, our consolidated balance sheet reflected the fair value, determined on a recurring basis based on Level 1 inputs, of our investment in Nexity to be $ 59,976 457,025
Computation of Loss per Share	xiii. Computation of Loss per Share Basic loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding. Diluted loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding plus additional common shares that would have been outstanding if dilutive potential common shares had been issued. For purposes of this calculation, convertible preferred stock, common stock dividends, warrants to acquire preferred stock convertible into common stock, and warrants and options to acquire common stock, are all considered common stock equivalents in periods in which they have a dilutive effect and are excluded from this calculation in periods in which these are anti-dilutive. The following table illustrates our computation of loss per share for the years ended December 31: Schedule of Computation of Loss Per Share 2022 2021 Numerator: Net loss attributable to common shareholders $ (17,803,953 ) $ (22,685,459 ) Denominator for basic and diluted loss per share: Weighted average common shares outstanding 11,058,356 6,636,523 Loss per common share - basic and diluted $ (1.61 ) $ (3.42 ) The following table presents securities that could potentially dilute basic loss per share in the future. For all periods presented, the potentially dilutive securities were not included in the computation of diluted loss per share because these securities would have been anti-dilutive for the years ended December 31: Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share 2022 2021 Stock options 1,307,822 1,333,101 Convertible debt 6,915,754 5,232,118 Common stock warrants 16,278,769 16,207,108 Convertible preferred stock: Series D Convertible Preferred 25,000 25,000 Series G Convertible Preferred 26,857 26,857 Series H Convertible Preferred 33,334 33,334 Series H2 Convertible Preferred 70,000 70,000 Series J Convertible Preferred 115,267 115,267 Series K Convertible Preferred 229,334 229,334 Series AA Convertible Preferred 8,645,000 8,649,000 Total potentially dilutive shares 33,647,137 31,921,119
Accounting for Income Taxes	xiv. Accounting for Income Taxes We account for income taxes under the asset and liability method, which requires recognition of deferred tax assets, subject to valuation allowances, and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and income tax purposes. The Company considers many factors when assessing the likelihood of future realization of our deferred tax assets, including recent cumulative earnings experience by taxing jurisdiction, expectations of future taxable income or loss, the carry-forward periods available to us for tax reporting purposes, and other relevant factors. A valuation allowance is established if it is more likely than not that all or a portion of the net deferred tax assets will not be realized. If substantial changes in the Company’s ownership should occur, as defined in Section 382 of the Internal Revenue Code, there could be significant limitations on the amount of net loss carry forwards that could be used to offset future taxable income. Tax positions must meet a “more likely than not” recognition threshold at the effective date to be recognized. At December 31, 2022 and 2021, the Company did not have any uncertain tax positions. No interest and penalties related to uncertain tax positions were accrued on December 31, 2022 and 2021.
Accounting for Stock-Based Compensation	xv. Accounting for Stock-Based Compensation We maintain equity compensation plans under which incentive stock options and non-qualified stock options are granted to employees, independent members of our Board of Directors and outside consultants. We recognize equity compensation expense over the requisite service period using the Black-Scholes formula to estimate the fair value of the stock options on the date of grant. Employee and non-employee awards are accounted for under ASC 718 where the awards are valued at grant date. Determining Fair Value of Stock Option Grants Valuation and Amortization Method Expected Term Compensation-Stock Compensation Expected Volatility Risk-Free Interest Rate Forfeitures Compensation-Stock Compensation The following table summarizes the assumptions we utilized for grants of stock options to the three sub-groups of our stock option recipients during the year ended December 31, 2021 (there were no options granted in 2022): Summary of Assumptions for Grants of Stock Options Assumptions CEO, other Officers and Employees Expected life 6.0 (yrs) Expected volatility 155.02 % Risk-free interest rate 0.62 % Forfeiture rate 5.00 % Expected dividend yield 0.0 % We recognized stock-based compensation expense of $ 215,098 254,615 Schedule of Stock Based Compensation Expense 2022 2021 Research and development $ 79,891 $ 128,094 Selling and marketing 24,687 22,233 General and administrative 110,520 104,288 Total stock-based compensation expense $ 215,098 $ 254,615 During the years ended December 31, 2022 and December 31, 2021, the total fair value of stock options awarded was $ 0 49,135 As of December 31, 2022, total unrecognized compensation cost related to the unvested stock-based awards was $ 15,312 1.09 As of December 31, 2021, total unrecognized compensation cost related to the unvested stock-based awards was $ 140,455 1.09
Advertising	xvi. Advertising Advertising costs are expensed as incurred. We incurred $ 487 17,594
Fair Value of Financial Instruments	xvii. Fair Value of Financial Instruments Due to their short maturities, the carrying amounts for cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and debt approximate their fair value. The carrying amount of long-term debt approximates fair value due to interest rates that approximate prevailing market rates.
Fair Value Measurements	xviii. Fair Value Measurements The Company follows the guidance of FASB ASC Topic 820, “ Fair Value Measurements and Disclosures ASC 820 The Company generally defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company uses a three-tier fair value hierarchy, which classifies the inputs used in measuring fair values. These tiers include: Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company has determined that its financial assets are currently classified within Level 1. The Company does not have any financial liabilities that are required to be measured on a recurring basis at December 31, 2022 and 2021. The following tables set forth the Company’s financial assets that were accounted for at fair value on a recurring basis as of December 31, 2022: Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis Fair value measurements at December 31, 2022 using: December 31, 2022 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Equity Securities 63,638 63,638 - - Total Financial Assets $ 63,638 $ 63,638 $ - $ - The following tables set forth the Company’s financial assets that were accounted for at fair value on a recurring basis as of December 31, 2021: Fair value measurements at December 31, 2021 using: December 31, 2021 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Equity Securities $ 59,976 $ 59,976 - - Total Financial Assets $ 59,976 $ 59,976 $ - $ -

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Schedule of Disaggregation of Revenue	In the following table, revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition. Schedule of Disaggregation of Revenue In thousands of US dollars ($) Year Ended December 31, Primary geographical markets 2022 2021 North America 1,191 1,179 Europe 144 289 Asia 394 534 1,729 2,002 In thousands of US dollars ($) Year Ended December 31, Major products/services lines 2022 2021 Hardware 761 1,104 Consumables 257 274 Contract research services 196 268 Agrochem Products 165 29 Sample preparation accessories 132 140 Technical support/extended service contracts 174 119 Shipping and handling 42 51 Other 2 17 1,729 2,002 In thousands of US dollars ($) Year Ended December 31, Timing of revenue recognition 2022 2021 Transferred at a point in time 1,359 1,674 Transferred over time 370 328 1,729 2,002
Schedule of Contract Balances	Contract balances Schedule of Contract Balances In thousands of US dollars ($) December 31, 2022 December 31, 2021 Receivables, which are included in ‘Accounts Receivable’ 295 155 Contract liabilities (deferred revenue) 60 41
Schedule of Future Related to Performance Obligations	The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. Schedule of Future Related to Performance Obligations In thousands of US dollars ($) 2023 2024 Total Extended warranty service 58 2 60
Schedule of Inventories	Inventories are valued at the lower of cost (average cost) or net realizable value. The cost of Barocyclers consists of the cost charged by the contract manufacturer. The cost of manufactured goods includes material, freight-in, direct labor, and applicable overhead. The composition of inventory as of December 31, is as follows: Schedule of Inventories 2022 2021 Raw materials $ 188,587 $ 296,892 Finished goods 1,480,769 1,193,158 Inventory reserve (982,973 ) (342,496 ) Total $ 686,383 $ 1,147,554
Schedule of Customer Concentration Risk Percentage	The following table illustrates the level of concentration of the below two groups within revenue as a percentage of total revenues during the years ended December 31: Schedule of Customer Concentration Risk Percentage 2022 2021 Top Five Customers 24 % 44 % Federal Agencies 0 % 6 % The following table illustrates the level of concentration of the below two groups within accounts receivable as a percentage of total accounts receivable balance as of December 31: 2022 2021 Top Five Customers 93 % 82 % Federal Agencies 0 % 5 %
Schedule of Computation of Loss Per Share	Schedule of Computation of Loss Per Share 2022 2021 Numerator: Net loss attributable to common shareholders $ (17,803,953 ) $ (22,685,459 ) Denominator for basic and diluted loss per share: Weighted average common shares outstanding 11,058,356 6,636,523 Loss per common share - basic and diluted $ (1.61 ) $ (3.42 )
Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share	The following table presents securities that could potentially dilute basic loss per share in the future. For all periods presented, the potentially dilutive securities were not included in the computation of diluted loss per share because these securities would have been anti-dilutive for the years ended December 31: Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share 2022 2021 Stock options 1,307,822 1,333,101 Convertible debt 6,915,754 5,232,118 Common stock warrants 16,278,769 16,207,108 Convertible preferred stock: Series D Convertible Preferred 25,000 25,000 Series G Convertible Preferred 26,857 26,857 Series H Convertible Preferred 33,334 33,334 Series H2 Convertible Preferred 70,000 70,000 Series J Convertible Preferred 115,267 115,267 Series K Convertible Preferred 229,334 229,334 Series AA Convertible Preferred 8,645,000 8,649,000 Total potentially dilutive shares 33,647,137 31,921,119
Summary of Assumptions for Grants of Stock Options	The following table summarizes the assumptions we utilized for grants of stock options to the three sub-groups of our stock option recipients during the year ended December 31, 2021 (there were no options granted in 2022): Summary of Assumptions for Grants of Stock Options Assumptions CEO, other Officers and Employees Expected life 6.0 (yrs) Expected volatility 155.02 % Risk-free interest rate 0.62 % Forfeiture rate 5.00 % Expected dividend yield 0.0 %
Schedule of Stock Based Compensation Expense	We recognized stock-based compensation expense of $ 215,098 254,615 Schedule of Stock Based Compensation Expense 2022 2021 Research and development $ 79,891 $ 128,094 Selling and marketing 24,687 22,233 General and administrative 110,520 104,288 Total stock-based compensation expense $ 215,098 $ 254,615
Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis	The following tables set forth the Company’s financial assets that were accounted for at fair value on a recurring basis as of December 31, 2022: Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis Fair value measurements at December 31, 2022 using: December 31, 2022 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Equity Securities 63,638 63,638 - - Total Financial Assets $ 63,638 $ 63,638 $ - $ - The following tables set forth the Company’s financial assets that were accounted for at fair value on a recurring basis as of December 31, 2021: Fair value measurements at December 31, 2021 using: December 31, 2021 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Equity Securities $ 59,976 $ 59,976 - - Total Financial Assets $ 59,976 $ 59,976 $ - $ -

Property and Equipment, net (Ta

Property and Equipment, net (Tables)	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment as of December 31, 2022 and 2021 consisted of the following components: Schedule of Property and Equipment 2022 2021 December 31, 2022 2021 Laboratory and manufacturing equipment $ 374,132 $ 353,379 Office equipment 194,999 194,999 Leasehold improvements 25,248 25,248 PCT collaboration, demonstration and leased systems 53,098 53,098 Total property and equipment 647,477 626,724 Less accumulated depreciation (544,126 ) (510,878 ) Net book value $ 103,351 $ 115,846

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	Schedule of Intangible Assets 2022 2021 December 31, 2022 2021 BaroFold Patents $ 750,000 $ 750,000 Less accumulated amortization (432,692 ) (346,154 ) Net book value $ 317,308 $ 403,846

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets and Deferred Tax Liabilities	Significant items making up the deferred tax assets and deferred tax liabilities as of December 31, 2022 and 2021 are as follows: Schedule of Deferred Tax Assets and Deferred Tax Liabilities 2022 2021 Long term deferred taxes: Inventory reserve $ 268,548 $ 93,570 Other accruals 99,362 91,792 Other 15,715 15,169 Non-cash, stock-based compensation, nonqualified 872,967 814,202 Impairment loss on investment 104,609 104,609 Operating loss carry forwards and tax credits 31,026,899 28,435,535 Less: valuation allowance (32,388,100 ) (29,554,877 ) Total net deferred tax assets $ - $ -
Schedule of U.S. Federal Statutory Tax Rate to Effective Income Tax Rate	The following table reconciles the U.S. Federal statutory tax rate to the Company’s effective tax rate: Schedule of U.S. Federal Statutory Tax Rate to Effective Income Tax Rate 2022 2021 Statutory U.S. Federal tax rate 21 % 21 % Permanent differences (0 ) (0 ) State tax expense (0 ) (0 ) Refundable AMT and R&D tax credit (0 ) (0 ) Valuation allowance (21 ) (21 ) Effective tax rate 0 % 0 %

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments Required Under Operating Leases	Following is a schedule by years of future minimum rental payments required under operating leases with initial or remaining non-cancelable lease terms for greater than one year as of December 31, 2022: Schedule of Future Minimum Rental Payments Required Under Operating Leases 2023 $ 149,300 2024 64,393 2025 66,969 2026 51,778 2027 - Thereafter - Total future undiscounted lease payments $ 332,440 Less imputed interest (50,345 ) Present value of lease liabilities $ 282,095
Schedule Of Right Of Use Asset And The Corresponding Lease Liability	Below is a table for the right of use asset and the corresponding lease liability in the consolidated balance sheets: Schedule Of Right Of Use Asset And The Corresponding Lease Liability Operating Leases December 31, 2022 December 31, 2021 Right of use asset $ 282,095 $ 395,565 Right of use lease liability, current $ 142,171 $ 132,996 Right of use lease liability, long term $ 139,924 $ 262,569 Total lease liability $ 282,095 $ 395,565
Schedule of Lease Cost for Operating Leases	The components of lease cost for operating leases for the years ended December 31, 2022 and 2021 are as follows: Schedule of Lease Cost for Operating Leases December 31, 2022 December 31, 2021 Operating lease cost $ 151,239 $ 87,383 Short-term lease cost 91,800 91,800 Total lease cost $ 243,039 $ 179,183

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Schedule of Other Debt	Schedule of Convertible Debts and Outstanding Balances December 31, 2022 December 31, 2021 Holders Interest Rate Conversion Price Principal Interest Rate Conversion Price Principal Main Investor 10 % $ 2.50 (1) $ 9,393,150 10 % $ 2.50 (1) $ 9,393,150 Others 0 24 % $ 2.50 7.50 (2) 8,886,036 1 24 % $ 2.50 (2) 4,983,312 Totals 18,279,186 14,376,462 Discount 455,517 1,536,649 Net $ 17,823,669 $ 12,839,813 Notes: (1) Conversion price of these note is $ 2.50 189,750 25 (2) Conversion price of these notes is $ 2.50 a. Notes are convertible before maturity at $ 2.50 2.50 b. Notes are convertible upon an Event of Default at 75 c. Notes are convertible at $ 2.50 75 d. Notes can be voluntary converted at lower of 1) $ 2.50 2.50 2.50 30 e. Notes can be voluntary converted at lower of 1) $ 2.50 2.50 2.50 25 f. Conversion price is lower of (i) $ 2.50 g. Note can be converted at a Voluntary Conversion Price which is the lower of 1) $ 2.50 2.50 70 h. Conversion price is $ 2.50 1 i. Notes can be voluntarily converted before maturity at $ 2.50 2.50 10 j. Notes can be converted at the lesser of $ 2.5 25 35 k. Some notes are not convertible until 180 days from the date of issuance of the Note and following an Event of Default will be convertible at the lowest trading price of the 20 days prior to conversion. The loan with a principal balance of $ 700,000 l. Some notes can be converted at the lesser of $ 2.50 25 5 m. Some notes are not convertible until 180 days from the date of issuance of the Note and following an Event of Default will be convertible at the lesser of $ 2.50 90 n. Some notes are convertible, upon an event of default, at the lowest closing bid price for the Company’s common stock for the five trading days prior to conversion. As of December 31, 2022, the approximate principal balance that are secured by the assets of the Company’s subsidiary, PBI Agrochem, Inc. is $ 352,188 During the year ended December 31, 2022, the Company extended 11 loans totaling $ 1,815,000 3,024,561 1,423,800 Standstill and Forbearance Agreements The Company has entered into Standstill and Forbearance Agreements with lenders who hold variable-rate convertible notes with a total principal as of December 31, 2022 of $ 574,984 . Pursuant to the Standstill and Forbearance Agreements, the lenders agreed to not convert any portion of their notes into shares of common stock at a variable rate until March 31, 2021 for convertible notes with a principal balance of $ 469,000 and until April 16, 2021 for convertible notes with a principal balance of $ 1.1 million. During the year ended December 31, 2022, the Company settled one note with total principal of $ 166,703 , leaving two final lenders (four notes) with total principal of $ 574,984 outstanding and incurred interest, penalties and fees of approximately $ 0.8 827,500 1.47 Convertible Loan Modifications and Extinguishments We refinanced certain convertible loans during the years ended December 31, 2022 and 2021 at substantially the same terms for extensions ranging over a period of three to six months. We amortized any remaining unamortized debt discount as of the modification date over the remaining, extended term of the new loans. We applied ASC 470 of modification accounting to the debt instruments which were modified during the period or those settled with new notes issued concurrently for the same amounts but different maturity dates. The terms such as the interest rate, prepayment penalties, and default rates will be the same over the new extensions. According to ASC 470, an exchange of debt instruments between or a modification of a debt instrument by a debtor and a creditor in a nontroubled debt situation is deemed to have been accomplished with debt instruments that are substantially different if the present value of the cash flows under the terms of the new debt instrument is at least 10 percent different from the present value of the remaining cash flows under the terms of the original instrument. If the terms of a debt instrument are changed or modified and the cash flow effect on a present value basis is less than 10 percent, the debt instruments are not considered to be substantially different and will be accounted for as modifications. The cash flows of new debt exceeded 10 751,335 1,061,073 Other Debt On October 11, 2019 we received a non-convertible loan with a one month 2 25,000 17,000 3.50 No notes in Other Debt are past due as of December 31, 2022. Schedule of Other Debt December 31, 2022 December 31, 2021 Holders Interest Rate Principal Interest Rate Principal Non-Convertible - ) $ 878,809 - ) $ 857,930 Merchant debt (3) 760,160 388,910 SBA ( 2 3.75 % 150,000 3.75 % 160,000 Totals 1,788,969 $ 1,406,840 Long Term 150,000 150,000 Short Term $ 1,638,969 $ 1,256,840 Notes: (1) Interest varies from 1 10 May 2, 2023 861,500 (2) The Company entered into a COVID-19 government loan in 2020, the Economic Injury Disaster Loan (or “EIDL”). The Company’s EIDL loan, $ 150,000 3.75 731 367,039 1 367,039 (3) During the years ended December 31, 2022 and 2021 we signed various Merchant Agreements which are secured by second position rights to all customer receipts until the loan has been repaid in full and subject to interest rates of 4.1 14 maturity dates ranged from April 4, 2023 to June 6, 2023. maturity dates ranged from January 7 to January 11, 2022.
Schedule of Other Debt	Schedule of Other Debt December 31, 2022 December 31, 2021 Holders Interest Rate Principal Interest Rate Principal Non-Convertible - ) $ 878,809 - ) $ 857,930 Merchant debt (3) 760,160 388,910 SBA ( 2 3.75 % 150,000 3.75 % 160,000 Totals 1,788,969 $ 1,406,840 Long Term 150,000 150,000 Short Term $ 1,638,969 $ 1,256,840 Notes: (1) Interest varies from 1 10 May 2, 2023 861,500 (2) The Company entered into a COVID-19 government loan in 2020, the Economic Injury Disaster Loan (or “EIDL”). The Company’s EIDL loan, $ 150,000 3.75 731 367,039 1 367,039 (3) During the years ended December 31, 2022 and 2021 we signed various Merchant Agreements which are secured by second position rights to all customer receipts until the loan has been repaid in full and subject to interest rates of 4.1 14 maturity dates ranged from April 4, 2023 to June 6, 2023. maturity dates ranged from January 7 to January 11, 2022.
Schedule of Related Party Debt	Schedule of Related Party Debt December 31, 2022 December 31, 2021 Holders Interest Rate Principal Interest Rate Principal Security Officers & Directors - ) $ 521,950 $ - Unsecured Other Related Parties 12 % 120,850 Unsecured Totals 642,800 Discount 7,915 Net $ 634,885 $ - Notes: (1) Interest varies from 12 120

Stockholders_ (Deficit) (Tables

Stockholders’ (Deficit) (Tables)	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Schedule of Preferred Stock Outstanding	Below is a summary table of the preferred stock: Schedule of Preferred Stock Outstanding December 31, 2022 December 31, 2021 Series D Convertible Preferred Stock, $ .01 850 300 300,000 $ 3 $ 3 Series G Convertible Preferred Stock, $ .01 240,000 80,570 806 806 Series H Convertible Preferred Stock, $ .01 10,000 10,000 100 100 Series J Convertible Preferred Stock, $ .01 6,250 3,458 35 35 Series K Convertible Preferred Stock, $ .01 15,000 6,880 68 68 Series AA Convertible Preferred Stock, $ .01 10,000 8,645 8,649 86 87 Series H2 Convertible Preferred Stock, $ .01 21 21 - - Series A Junior Participating Preferred Stock, $ .01 20,000 no - - Series A Convertible Preferred Stock, $ .01 313,960 no - - Series B Convertible Preferred Stock, $ .01 279,256 no - - Series C Convertible Preferred Stock, $ .01 88,098 no - - Series E Convertible Preferred Stock, $ .01 500 no - - Total Convertible Preferred Shares $ 1,098 $ 1,099
Schedule of Concerning Options and Warrants Outstanding and Exercisable	The following tables summarize information concerning options and warrants outstanding and exercisable: Schedule of Concerning Options and Warrants Outstanding and Exercisable Stock Options Warrants Total Shares Weighted Shares Weighted Shares Exercisable Balance outstanding, December 31, 2020 1,355,901 $ 0.71 14,434,702 $ 3.50 15,790,603 15,302,830 Granted 24,000 2.17 2,235,408 3.57 2,259,408 Exercised (21,411 ) 0.69 (187,500 ) 3.50 (208,911 ) Expired - - (275,502 ) 3.50 (275,502 ) Forfeited (25,389 ) 0.69 - - (25,389 ) Balance outstanding, December 31, 2021 1,333,101 $ 0.72 16,207,108 $ 3.50 17,540,209 17,308,567 Granted - - 277,500 3.50 277,500 Exercised (25,279 ) 0.69 - - (25,279 ) Expired - - (205,839 ) 3.50 (205,839 ) Forfeited - - - - - Balance outstanding, December 31, 2022 1,307,822 $ 0.72 16,278,769 $ 3.50 17,586,591 17,570,591
Schedule of Share-based Compensation Stock Option Plans by Exercise Price Range	Schedule of Share-based Compensation Stock Option Plans by Exercise Price Range Options Outstanding Options Exercisable Weighted Average Weighted Average Range of Number of Remaining Exercise Number of Remaining Exercise $ 0.69 $ 1.00 1,283,822 6.7 $ 0.69 1,283,822 6.7 $ 0.69 $ 1.01 $ 3.00 24,000 8.1 $ 2.17 8,000 8.1 $ 2.17 1,307,822 6.7 $ 0.72 1,291,822 6.7 $ 0.69
Schedule of Loans Obligated to Issue Shares	As profiled in the following table, for seven loans we are obligated to issue common stock if not paid by defined dates. Schedule of Loans Obligated to Issue Shares Loan Issuance Loan Percentage of Loan Principal Defined Shares Issuable Loan Date Principal Issuable Date Frequency Loan 1(1) July 21, 2020 $ 115,000 0.0435 % September 30, 2020 Monthly Loan 2 September 21, 2020 $ 345,000 0.0362 % November 16, 2020 Weekly Loan 5 October 22, 2020 $ 115,000 0.0652 % December 1, 2020 Weekly Loan 6 October 21, 2021 $ 189,750 0.0435 % January 2, 2022 Monthly Loan 7 November 1, 2021 $ 189,750 0.0435 % January 2, 2022 Monthly

Schedule of Disaggregation of R

Schedule of Disaggregation of Revenue (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Product Information [Line Items]
Revenue	$ 1,729,343	$ 2,002,365
Hardware [Member]
Product Information [Line Items]
Revenue	761,000	1,104,000
Consumables [Member]
Product Information [Line Items]
Revenue	257,000	274,000
Contract Research Services [Member]
Product Information [Line Items]
Revenue	196,000	268,000
Agrochem Products [Member]
Product Information [Line Items]
Revenue	165,000	29,000
Sample Preparation Accessories [Member]
Product Information [Line Items]
Revenue	132,000	140,000
Technical Support/Extended Service Contracts [Member]
Product Information [Line Items]
Revenue	174,000	119,000
Shipping and Handling [Member]
Product Information [Line Items]
Revenue	42,000	51,000
Other [Member]
Product Information [Line Items]
Revenue	2,000	17,000
Transferred at a Point In Time [Member]
Product Information [Line Items]
Revenue	1,359,000	1,674,000
Transferred Over At Time [Member]
Product Information [Line Items]
Revenue	370,000	328,000
North America [Member]
Product Information [Line Items]
Revenue	1,191,000	1,179,000
Europe [Member]
Product Information [Line Items]
Revenue	144,000	289,000
Asia [Member]
Product Information [Line Items]
Revenue	$ 394,000	$ 534,000

Schedule of Contract Balances (

Schedule of Contract Balances (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Receivables, which are included in ‘Accounts Receivable’	$ 295	$ 155
Contract liabilities (deferred revenue)	$ 60	$ 41

Schedule of Future Related to P

Schedule of Future Related to Performance Obligations (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Extended warranty service	$ 60
2023 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Extended warranty service	58
Two Thousand And Twenty Four [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Extended warranty service	$ 2

Schedule of Inventories (Detail

Schedule of Inventories (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Raw materials	$ 188,587	$ 296,892
Finished goods	1,480,769	1,193,158
Inventory reserve	(982,973)	(342,496)
Total	$ 686,383	$ 1,147,554

Schedule of Customer Concentrat

Schedule of Customer Concentration Risk Percentage (Details) - Customer Concentration Risk [Member]	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Top Five Customers [Member] | Revenue Benchmark [Member]
Product Information [Line Items]
Concentration credit risk percentage	24%	44%
Top Five Customers [Member] | Accounts Receivable [Member]
Product Information [Line Items]
Concentration credit risk percentage	93%	82%
Federal Agencies [Member] | Revenue Benchmark [Member]
Product Information [Line Items]
Concentration credit risk percentage	0%	6%
Federal Agencies [Member] | Accounts Receivable [Member]
Product Information [Line Items]
Concentration credit risk percentage	0%	5%

Schedule of Computation of Loss

Schedule of Computation of Loss Per Share (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Net loss attributable to common shareholders	$ (17,803,953)	$ (22,685,459)
Weighted average common shares outstanding	11,058,356	6,636,523
Loss per common share - basic and diluted	$ (1.61)	$ (3.42)

Schedule of Anti-dilutive Secur

Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	33,647,137	31,921,119
Employee Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	1,307,822	1,333,101
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	6,915,754	5,232,118
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	16,278,769	16,207,108
Series D Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	25,000	25,000
Series G Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	26,857	26,857
Series H Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	33,334	33,334
Series H2 Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	70,000	70,000
Series J Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	115,267	115,267
Series K Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	229,334	229,334
Series AA Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	8,645,000	8,649,000

Summary of Assumptions for Gran

Summary of Assumptions for Grants of Stock Options (Details) - CEO, other Officers and Employees [Member]	12 Months Ended
	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected life	6 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate	155.02%
Risk-free interest rate	0.62%
Forfeiture rate	5%
Expected dividend yield	0%

Schedule of Stock Based Compens

Schedule of Stock Based Compensation Expense (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Total stock-based compensation expense	$ 215,098	$ 254,615
Research and Development Expense [Member]
Total stock-based compensation expense	79,891	128,094
Selling and Marketing Expense [Member]
Total stock-based compensation expense	24,687	22,233
General and Administrative Expense [Member]
Total stock-based compensation expense	$ 110,520	$ 104,288

Schedule of Assets and Liabilit

Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Financing Receivable, Past Due [Line Items]
Total Financial Assets	$ 63,638	$ 59,976
Fair Value, Inputs, Level 1 [Member]
Financing Receivable, Past Due [Line Items]
Total Financial Assets	63,638	59,976
Fair Value, Inputs, Level 2 [Member]
Financing Receivable, Past Due [Line Items]
Total Financial Assets
Fair Value, Inputs, Level 3 [Member]
Financing Receivable, Past Due [Line Items]
Total Financial Assets
Equity Securities [Member]
Financing Receivable, Past Due [Line Items]
Total Financial Assets	63,638	59,976
Equity Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Financing Receivable, Past Due [Line Items]
Total Financial Assets	63,638	59,976
Equity Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Financing Receivable, Past Due [Line Items]
Total Financial Assets
Equity Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Financing Receivable, Past Due [Line Items]
Total Financial Assets

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Aug. 30, 2020
Cumulative effect of adoption, adjustment in additional paid in capital	$ 69,006,145	$ 64,261,048		$ 2,728,243
Cumulative effect of adoption, adjustment in accumulated deficit	(133,826,205)	(118,277,468)		2,255,216
Stockholders deficit	(32,686,371)	(22,208,961)	$ (16,917,592)	$ 473,027
Intangible assets	317,308	403,846
Fair value of stock options awarded	0	49,135
Share-based payment arrangement, nonvested award, cost not yet recognized, amount	$ 15,312	$ 140,455
Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition	1 year 1 month 2 days	1 year 1 month 2 days
Advertising costs	$ 487	$ 17,594
Everest [Member]
Sale of stock number of shares received	100,250
Number of common stock shares exchanged during the period	33,334
Nexity Global SA [Member]
Sale of stock number of shares received	100,250
Investment Owned, at Fair Value	$ 63,638	59,976
Unrealized gain	$ 3,662	$ 457,025

Schedule of Property and Equipm

Schedule of Property and Equipment (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Laboratory and manufacturing equipment	$ 374,132	$ 353,379
Office equipment	194,999	194,999
Leasehold improvements	25,248	25,248
PCT collaboration, demonstration and leased systems	53,098	53,098
Total property and equipment	647,477	626,724
Less accumulated depreciation	(544,126)	(510,878)
Net book value	$ 103,351	$ 115,846

Property and Equipment, net (De

Property and Equipment, net (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 33,250	$ 23,589

Schedule of Intangible Assets (

Schedule of Intangible Assets (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
BaroFold Patents	$ 750,000	$ 750,000
Less accumulated amortization	(432,692)	(346,154)
Net book value	$ 317,308	$ 403,846

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Amortization expense	$ 86,538	$ 86,538
Intangible assets amortization of straight line period	9 years
Amortization expense, year one	$ 80,000
Amortization expense, year two	80,000
Amortization expense, year three	80,000
Amortization expense, year four	80,000
Amortization expense, year five	80,000
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization expense	$ 80,000

Retirement Plan (Details Narrat

Retirement Plan (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Retirement Benefits [Abstract]
Payment for pension benefits	$ 12,777	$ 11,752

Schedule of Deferred Tax Assets

Schedule of Deferred Tax Assets and Deferred Tax Liabilities (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Long term deferred taxes:
Inventory reserve	$ 268,548	$ 93,570
Other accruals	99,362	91,792
Other	15,715	15,169
Non-cash, stock-based compensation, nonqualified	872,967	814,202
Impairment loss on investment	104,609	104,609
Operating loss carry forwards and tax credits	31,026,899	28,435,535
Less: valuation allowance	(32,388,100)	(29,554,877)
Total net deferred tax assets

Schedule of U.S. Federal Statut

Schedule of U.S. Federal Statutory Tax Rate to Effective Income Tax Rate (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Statutory U.S. Federal tax rate	21%	21%
Permanent differences	(0.00%)	(0.00%)
State tax expense	(0.00%)	(0.00%)
Refundable AMT and R&D tax credit	(0.00%)	(0.00%)
Valuation allowance	(21.00%)	(21.00%)
Effective tax rate	0%	0%

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2017
Operating Loss Carryforwards [Line Items]
Unrecognized tax benefits, income tax penalties and interest accrued	$ 0	$ 0
Net operating loss	(4,898,289)	$ (4,185,147)	$ 70,711,859
Domestic Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	$ 110,385,351
Operating loss carry-forwards expire term	2023 through 2037
Domestic Tax Authority [Member] | Research Tax Credit Carryforward [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carry-forwards expire term	2022 through 2037
Income tax examination, description		Under the Tax Reform Act, NOL’s generated after December 31, 2017 can offset only 80% of a corporation’s taxable income in any year.
Deferred tax assets, tax credit carryforwards	$ 1,338,308
State and Local Jurisdiction [Member]
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	$ 106,651,967
State and Local Jurisdiction [Member] | Research Tax Credit Carryforward [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carry-forwards expire term	2023 through 2034
Deferred tax assets, tax credit carryforwards	$ 356,424

Schedule of Future Minimum Rent

Schedule of Future Minimum Rental Payments Required Under Operating Leases (Details)	Dec. 31, 2022 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2023	$ 149,300
2024	64,393
2025	66,969
2026	51,778
2027
Thereafter
Total future undiscounted lease payments	332,440
Less imputed interest	(50,345)
Present value of lease liabilities	$ 282,095

Schedule Of Right Of Use Asset

Schedule Of Right Of Use Asset And The Corresponding Lease Liability (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Total lease liability	$ 282,095	$ 395,565
Right of use lease liability, current	142,171	132,996
Right of use lease liability, long term	$ 139,924	$ 262,569

Schedule of Lease Cost for Oper

Schedule of Lease Cost for Operating Leases (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Operating lease cost	$ 151,239	$ 87,383
Short-term lease cost	91,800	91,800
Total lease cost	$ 243,039	$ 179,183

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative) - USD ($)		1 Months Ended	12 Months Ended
	Aug. 09, 2021	Apr. 30, 2012	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Right-of-use asset			$ 282,095	$ 395,565
Operating lease liability			282,095
Operating lease			$ 113,470	$ 65,194
Weighted-average remaining lease term			2 years 11 months 15 days	3 years 8 months 12 days
Weighted-average discount rate			12%	12%
Finance lease liability			$ 0	$ 0
Expenses			6,627,632	6,187,512
Battelle Memorial Institute [Member]
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Mimimum royalty fee					$ 5,000	$ 4,000	$ 3,000	$ 2,000	$ 1,200
Target Discovery Inc [Member]
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Mimimum royalty fee			60,000	60,000
Payments for fees		$ 1,400
Professional and contract services expense		$ 2,000
Expenses			69,300	82,800
Medford lease [Member]
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Annual cost of living payment			$ 7,282
Lessee operating lease description			The lease shall be automatically extended for additional three years unless either party terminates at least six months prior to the expiration of the current lease term.
Right-of-use asset			$ 221,432
Operating lease liability			$ 221,432
Estimated borrowing rate			12%
Sparks lease [Member]
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Lessee operating lease description	On August 9, 2021, we entered into an operating lease agreement for our warehouse space in Sparks, NV (the “Sparks Lease”) for the period from September 1, 2021 through September 30, 2026. The lease contains escalating payments during the lease period. The lease can be extended for an additional three years if the Company provides notice at least six months prior to the expiration of the current lease term.
Right-of-use asset			$ 239,327
Operating lease liability				$ 239,327
Estimated borrowing rate			12%
Corporate Office [Member]
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Lease monthly payments			$ 7,650
Lease expiration date			Dec. 31, 2023

Schedule of Other Debt (Details

Schedule of Other Debt (Details) - USD ($)		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Conversion		$ 2.50
Totals		$ 18,279,186	$ 14,376,462
Totals		455,517	1,536,649
Totals		17,823,669	12,839,813
Totals, Principal		1,788,969	1,406,840
Long Term, Principal		150,000	150,000
Short Term, Principal		$ 1,638,969	$ 1,256,840
Non Convertible [Member]
Debt Instrument [Line Items]
Interest Rate	[1]
Totals, Principal		$ 878,809	$ 857,930
Merchant Debt [Member]
Debt Instrument [Line Items]
Totals, Principal	[2]	$ 760,160	$ 388,910
SBA [Member]
Debt Instrument [Line Items]
Interest Rate	[3]	3.75%	3.75%
Totals, Principal	[3]	$ 150,000	$ 160,000
Minimum [Member]
Debt Instrument [Line Items]
Interest Rate	[3]	1%
Maximum [Member]
Debt Instrument [Line Items]
Interest Rate	[3]	10%
Investor [Member]
Debt Instrument [Line Items]
Interest Rate		10%	10%
Conversion	[4]	$ 2.50	$ 2.50
Totals		$ 9,393,150	$ 9,393,150
Others [Member]
Debt Instrument [Line Items]
Conversion	[5]		$ 2.50
Totals		$ 8,886,036	$ 4,983,312
Others [Member] | Minimum [Member]
Debt Instrument [Line Items]
Interest Rate		0%	1%
Conversion		$ 2.50
Others [Member] | Maximum [Member]
Debt Instrument [Line Items]
Interest Rate		24%	24%
Conversion		$ 7.50
[1]Interest varies from 1 10 May 2, 2023 861,500 4.1 14 maturity dates ranged from April 4, 2023 to June 6, 2023. maturity dates ranged from January 7 to January 11, 2022. 150,000 3.75 731 367,039 1 367,039 2.50 189,750 25 2.50

Schedule of Convertible Debts a

Schedule of Convertible Debts and Outstanding Balances (Details) (Parenthetical)	12 Months Ended
	Dec. 31, 2022 USD ($) Integer $ / shares	Aug. 31, 2021 USD ($)	Feb. 12, 2020 USD ($)
Short-Term Debt [Line Items]
Debt instrument, convertible price per shares	$ 2.50
Debt default amount | $	$ 1
Debt instrument, convertible, conversion price	$ 2.50
Debt default convertible conversion ratio	75%
Debt instrument, convertible, conversion price, Increase	$ 2.50
Debt instrument, convertible, conversion price, decrease	$ 2.50
Percentage of price	10%
Convertible lesser per share	$ 2.5
Convertible lesser Percent	25%
Original debt, interest rate of debt	35%
Principal balance | $	$ 12,000,000	$ 9,393,150	$ 1,535,500
Trading day | Integer	5
Default convertible lesser price per share	$ 2.50
Debt instrument trading percent	90%
Chief Executive Officer [Member]
Short-Term Debt [Line Items]
Principal balance | $	$ 700,000
Convertible Debt [Member]
Short-Term Debt [Line Items]
Debt instrument, convertible price per shares	$ 2.50
Debt default amount | $	$ 189,750
Debt instrument lowest trading price	25%
Convertible Debt One [Member]
Short-Term Debt [Line Items]
Debt instrument, convertible price per shares	$ 2.50
Convertible Debt Two [Member]
Short-Term Debt [Line Items]
Debt instrument lowest trading price	30%
Convertible Debt Three [Member]
Short-Term Debt [Line Items]
Debt instrument lowest trading price	25%
Convertible Debt Four [Member]
Short-Term Debt [Line Items]
Debt instrument lowest trading price	70%

Schedule of Other Debt (Detai_2

Schedule of Other Debt (Details) (Parenthetical) - USD ($)		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Debt instrument, maturity date		May 02, 2023
Non- convertible debt amount		$ 861,500
Note payable		$ 150,000
Accrued interest rate percent		3.75%
Debt Instrument periodic payment		$ 731
Debt instrument, maturity date description		March, 2020 to December, 2023
Merchant Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date description		maturity dates ranged from April 4, 2023 to June 6, 2023.	maturity dates ranged from January 7 to January 11, 2022.
Payroll Protection Program [Member]
Debt Instrument [Line Items]
Borrowed amount				$ 367,039
Debt interest rate				1%
Paycheck Protection Programme [Member]
Debt Instrument [Line Items]
Borrowed amount			$ 367,039
Minimum [Member]
Debt Instrument [Line Items]
Debt interest rate	[1]	1%
Minimum [Member] | Merchant Agreement [Member]
Debt Instrument [Line Items]
Debt interest rate		4.10%
Maximum [Member]
Debt Instrument [Line Items]
Debt interest rate	[1]	10%
Maximum [Member] | Merchant Agreement [Member]
Debt Instrument [Line Items]
Debt interest rate		14%
[1]The Company entered into a COVID-19 government loan in 2020, the Economic Injury Disaster Loan (or “EIDL”). The Company’s EIDL loan, $ 150,000 3.75 731 367,039 1 367,039

Schedule of Related Party Debt

Schedule of Related Party Debt (Details) - USD ($)		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021
Defined Benefit Plan Disclosure [Line Items]
Totals, Principle		$ 731
Net, Principal		$ 634,885
Officers & Directors [Member]
Defined Benefit Plan Disclosure [Line Items]
Interest Rate	[1]
Totals, Principle		$ 521,950
Other Related Parties [Member]
Defined Benefit Plan Disclosure [Line Items]
Interest Rate		12%
Totals, Principle		$ 120,850
Related Party [Member]
Defined Benefit Plan Disclosure [Line Items]
Totals, Principle		642,800
Discount, Principal		7,915
Net, Principal		$ 634,885
[1]Interest varies from 12 120

Schedule of Related Party Deb_2

Schedule of Related Party Debt (Details) (Parenthetical)	Dec. 31, 2022
Minimum [Member]
Debt Instrument [Line Items]
Interest Rate	1%	[1]
Maximum [Member]
Debt Instrument [Line Items]
Interest Rate	10%	[1]
Related Party [Member] | Minimum [Member]
Debt Instrument [Line Items]
Interest Rate	12%
Related Party [Member] | Maximum [Member]
Debt Instrument [Line Items]
Interest Rate	120%
[1]The Company entered into a COVID-19 government loan in 2020, the Economic Injury Disaster Loan (or “EIDL”). The Company’s EIDL loan, $ 150,000 3.75 731 367,039 1 367,039

Debt (Details Narrative)

Debt (Details Narrative) - USD ($)		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Aug. 31, 2021	Apr. 16, 2021	Mar. 31, 2021	Feb. 12, 2020
Short-Term Debt [Line Items]
Net proceeds from convertible debt		$ 4,907,222	$ 5,514,250
Common stock issuance conversion price		$ 2.50
Deferred cost current and non-current		$ 541,313
Repayment of convertible debt		$ 1,522,494	1,833,295
Debt instrument maturity date description		March, 2020 to December, 2023
Debt instrument, face amount.		$ 12,000,000		$ 9,393,150			$ 1,535,500
Debt face amount		1,815,000
Increase debt instrument face amount		$ 3,024,561
Common stock issued for debt settlement, shares		10,000
Losses on extinguishment of debt		$ (2,331,398)	(130,279)
Repayments of Related Party Debt		315,300	354,600
Unamortized, debt discount		455,517	$ 1,536,649
Lenders [Member]
Short-Term Debt [Line Items]
Warrants exercise price per share			$ 3.5
Lenders [Member] | Standstill and Forbearance Agreements [Member]
Short-Term Debt [Line Items]
Debt instrument, face amount.		574,984
Convertible debt					$ 1,100,000	$ 469,000
Three Lenders [Member]
Short-Term Debt [Line Items]
Repayment of convertible debt		166,703
Three Lenders [Member] | Forbearance Agreements [Member]
Short-Term Debt [Line Items]
Repayment of convertible debt		574,984	$ 827,500
Interest payable current and non current			$ 1,470,000
Four Lenders [Member] | Forbearance Agreements [Member]
Short-Term Debt [Line Items]
Interest payable current and non current		800,000
PBI Agrochem Inc [Member]
Short-Term Debt [Line Items]
Debt instrument, face amount.		$ 352,188
Warrant [Member]
Short-Term Debt [Line Items]
Common stock issued for debt settlement, shares		277,500	2,235,408
Warrants exercise price per share		$ 3.50
Common Stock [Member]
Short-Term Debt [Line Items]
Common stock issued for debt settlement, shares		1,423,800
Minimum [Member]
Short-Term Debt [Line Items]
Debt instrument, interest rate, stated percentage	[1]	1%
Minimum [Member] | Warrant [Member]
Short-Term Debt [Line Items]
Debt instrument term		3 years	3 years
Common stock issuance conversion price			$ 3.50
Minimum [Member] | Common Stock [Member]
Short-Term Debt [Line Items]
Warrants exercise price per share			$ 3.50
Maximum [Member]
Short-Term Debt [Line Items]
Debt instrument, interest rate, stated percentage	[1]	10%
Maximum [Member] | Warrant [Member]
Short-Term Debt [Line Items]
Debt instrument term		5 years	5 years
Common stock issuance conversion price			$ 5
Maximum [Member] | Common Stock [Member]
Short-Term Debt [Line Items]
Warrants exercise price per share			$ 5
Convertible Debt [Member]
Short-Term Debt [Line Items]
Net proceeds from convertible debt		$ 4,900,000	$ 5,500,000
Debt Instrument, convertible, beneficial conversion feature			1,300,000
Convertible Debt [Member] | Warrant [Member]
Short-Term Debt [Line Items]
Convertible notes debt fair value		$ 93,576	1,400,000
Convertible Debt [Member] | Convertible Common Stock [Member]
Short-Term Debt [Line Items]
Common stock issuance conversion price		$ 2.50
Convertible notes debt fair value		$ 873,854	$ 646,718
Convertible Debt [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Debt instrument term		1 month	6 months
Debt instrument, interest rate, stated percentage		0%	10%
Convertible Debt [Member] | Minimum [Member] | Convertible Common Stock [Member]
Short-Term Debt [Line Items]
Common stock issuance conversion price			$ 2.50
Convertible Debt [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Debt instrument term		12 months	12 months
Debt instrument, interest rate, stated percentage		18%	18%
Convertible Debt [Member] | Maximum [Member] | Convertible Common Stock [Member]
Short-Term Debt [Line Items]
Common stock issuance conversion price			$ 3
Convertible Notes [Member]
Short-Term Debt [Line Items]
Amortized, debt discount		$ 1,694,028	$ 6,700,000
New Loan [Member]
Short-Term Debt [Line Items]
Debt instrument, interest rate, stated percentage		10%
Losses on extinguishment of debt		$ 751,335	$ 1,061,073
Non Convertible [Member]
Short-Term Debt [Line Items]
Debt instrument, interest rate, stated percentage	[2]
Non Convertible [Member] | Private Investor [Member]
Short-Term Debt [Line Items]
Debt instrument term		1 month
Debt instrument, interest rate, stated percentage		2%
Proceeds from loans		$ 25,000
Non Convertible [Member] | Series AA Preferred Stock [Member] | Private Investor [Member]
Short-Term Debt [Line Items]
Common stock issued for debt settlement, shares		17,000
Warrants exercise price per share		$ 3.50
Short-term Non-Convertible Loan [Member]
Short-Term Debt [Line Items]
Amortized, debt discount		$ 83,835	$ 49,564
Proceeds from short-term debt		958,100	254,600
Repayments of Related Party Debt		315,300	354,600
Debt conversion principal amount			66,000
Debt conversion interest amount			107,625
Unamortized, debt discount		$ 7,915	$ 0
Short-term Non-Convertible Loan [Member] | Series AA Preferred Stock [Member]
Short-Term Debt [Line Items]
Common stock issued for debt settlement, shares			69.5
Warrants exercise price per share			$ 3.50
Number of warrants issued			69,450
Short-term Non-Convertible Loan [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Debt instrument, interest rate, stated percentage		12%	0%
Short-term Non-Convertible Loan [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Debt instrument, interest rate, stated percentage		120%	15%
[1]The Company entered into a COVID-19 government loan in 2020, the Economic Injury Disaster Loan (or “EIDL”). The Company’s EIDL loan, $ 150,000 3.75 731 367,039 1 367,039 1 10 May 2, 2023 861,500

Schedule of Preferred Stock Out

Schedule of Preferred Stock Outstanding (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Class of Stock [Line Items]
Total Convertible Preferred Shares	$ 1,098	$ 1,099
Series D Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Total Convertible Preferred Shares	3	3
Series G Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Total Convertible Preferred Shares	806	806
Series H Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Total Convertible Preferred Shares	100	100
Series J Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Total Convertible Preferred Shares	35	35
Series K Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Total Convertible Preferred Shares	68	68
Series AA Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Total Convertible Preferred Shares	86	87
Series H2 Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Total Convertible Preferred Shares
Series A Junior Participating Preferred Stock [Member]
Class of Stock [Line Items]
Total Convertible Preferred Shares
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Total Convertible Preferred Shares
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Total Convertible Preferred Shares
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Total Convertible Preferred Shares
Series E Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Total Convertible Preferred Shares

Schedule Of Preferred Stock O_2

Schedule Of Preferred Stock Outstanding (Details) (Parenthetical) - USD ($)	Dec. 31, 2022	Dec. 31, 2021	May 20, 2013	Jan. 04, 2013	Dec. 28, 2012	Nov. 15, 2012	Nov. 11, 2011
Series D Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.01	$ 0.01					$ 0.01
Preferred stock, shares authorized	850	850
Preferred stock, shares issued	300	300
Preferred stock, shares outstanding	300	300
Preferred stock, liquidation preference value	$ 300,000	$ 300,000
Preferred stock, par value	$ 0.01	$ 0.01					$ 0.01
Series H Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.01	$ 0.01		$ 0.01
Preferred stock, shares authorized	10,000	10,000		10,000	10,000
Preferred stock, shares issued	10,000	10,000
Preferred stock, shares outstanding	10,000	10,000
Preferred stock, par value	$ 0.01	$ 0.01		$ 0.01
Series G Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.01	$ 0.01				$ 0.01
Preferred stock, shares authorized	240,000	240,000
Preferred stock, shares issued	80,570	80,570
Preferred stock, shares outstanding	80,570	80,570
Preferred stock, par value	$ 0.01	$ 0.01				$ 0.01
Series J Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.01	$ 0.01	$ 0.01
Preferred stock, shares authorized	6,250
Preferred stock, shares outstanding		3,458
Preferred stock, par value	$ 0.01	$ 0.01	$ 0.01
Series K Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	15,000	15,000
Preferred stock, shares issued	6,880
Preferred stock, shares outstanding	6,880	6,880
Preferred stock, par value	$ 0.01	$ 0.01
Series AA Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	10,000	10,000
Preferred stock, shares issued	8,645	8,649
Preferred stock, shares outstanding	8,645	8,649
Preferred stock, par value	$ 0.01	$ 0.01
Series H2 Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	21	21
Preferred stock, shares issued	21	21
Preferred stock, shares outstanding	21	21
Preferred stock, par value	$ 0.01	$ 0.01
Series A Junior Participating Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	20,000	20,000
Preferred stock, shares outstanding	0	0
Preferred stock, par value	$ 0.01	$ 0.01
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	313,960	313,960
Preferred stock, shares outstanding	0	0
Preferred stock, par value	$ 0.01	$ 0.01
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	279,256	279,256
Preferred stock, shares outstanding	0	0
Preferred stock, par value	$ 0.01	$ 0.01
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	88,098	88,098
Preferred stock, shares outstanding	0	0
Preferred stock, par value	$ 0.01	$ 0.01
Series E Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	500	500
Preferred stock, shares outstanding	0	0
Preferred stock, par value	$ 0.01	$ 0.01

Schedule of Concerning Options

Schedule of Concerning Options and Warrants Outstanding and Exercisable (Details) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares, Beginning balance	17,540,209	15,790,603
Exercisable, Beginning balance	17,308,567	15,302,830
Shares, Granted	277,500	2,259,408
Shares, Exercised	(25,279)	(208,911)
Shares, Expired	(205,839)	(275,502)
Shares, Forfeited		(25,389)
Shares, Ending balance	17,586,591	17,540,209
Exercisable, Ending balance	17,570,591	17,308,567
Stock Options [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares, Beginning balance	1,333,101	1,355,901
Weighted average price per share, Beginning balance	$ 0.72	$ 0.71
Shares, Granted		24,000
Weighted average price per share, Granted		$ 2.17
Shares, Exercised	(25,279)	(21,411)
Weighted average price per share, Exercised	$ 0.69	$ 0.69
Shares, Expired
Weighted average price per share, Expired
Shares, Forfeited		(25,389)
Weighted average price per share, Forfeited		$ 0.69
Shares, Ending balance	1,307,822	1,333,101
Weighted average price per share, Ending balance	$ 0.72	$ 0.72
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares, Beginning balance	16,207,108	14,434,702
Weighted average price per share, Beginning balance	$ 3.50	$ 3.50
Shares, Granted	277,500	2,235,408
Weighted average price per share, Granted	$ 3.50	$ 3.57
Shares, Exercised		(187,500)
Weighted average price per share, Exercised		$ 3.50
Shares, Expired	(205,839)	(275,502)
Weighted average price per share, Expired	$ 3.50	$ 3.50
Shares, Forfeited
Weighted average price per share, Forfeited
Shares, Ending balance	16,278,769	16,207,108
Weighted average price per share, Ending balance	$ 3.50	$ 3.50

Schedule of Share-based Compens

Schedule of Share-based Compensation Stock Option Plans by Exercise Price Range (Details)	12 Months Ended
	Dec. 31, 2022 $ / shares shares
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Number Outstanding | shares	1,307,822
Options Outstanding, Remaining Contractual Life (In Years)	6 years 8 months 12 days
Options Outstanding, Weighted Average Exercise Price	$ 0.72
Options Exercisable, Number Exercisable | shares	1,291,822
Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term	6 years 8 months 12 days
Options Exercisable, Weighted Average Exercise Price	$ 0.69
Exercise Price Range One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price lower range limit	0.69
Exercise price upper range limit	$ 1
Options Outstanding, Number Outstanding | shares	1,283,822
Options Outstanding, Remaining Contractual Life (In Years)	6 years 8 months 12 days
Options Outstanding, Weighted Average Exercise Price	$ 0.69
Options Exercisable, Number Exercisable | shares	1,283,822
Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term	6 years 8 months 12 days
Options Exercisable, Weighted Average Exercise Price	$ 0.69
Exercise Price Range Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price lower range limit	1.01
Exercise price upper range limit	$ 3
Options Outstanding, Number Outstanding | shares	24,000
Options Outstanding, Remaining Contractual Life (In Years)	8 years 1 month 6 days
Options Outstanding, Weighted Average Exercise Price	$ 2.17
Options Exercisable, Number Exercisable | shares	8,000
Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term	8 years 1 month 6 days
Options Exercisable, Weighted Average Exercise Price	$ 2.17

Schedule of Loans Obligated to

Schedule of Loans Obligated to Issue Shares (Details) - USD ($)		12 Months Ended
	Dec. 23, 2020	Dec. 31, 2022	Aug. 31, 2021	Feb. 12, 2020
Short-Term Debt [Line Items]
Loan Principal		$ 12,000,000	$ 9,393,150	$ 1,535,500
Debt Instrument, Maturity Date		May 02, 2023
Shares Issuance Frequency	we are obligated to issue 100,000 warrants if the loan is not repaid before January 23, 2021 and an additional 10,000 shares of common stock and 100,000 warrants if the loan is not repaid before February 23, 2021. We are also obligated to issue 10,000 shares of common stock and 200,000 warrants if the loan is not repaid before March 23, 2021. During the year ended December 31, 2021 the Company issued 400,000 warrants to this lender ($3.50 exercise price and five-year term) with a fair value of $600,298. The Company is also obligated to issue 10,000 shares of common stock to this lender every 31 days up to the loan’s maturity date on June 23, 2021.
Loans 1 [Member]
Short-Term Debt [Line Items]
Debt Instrument, Issuance Date		Jul. 21, 2020
Loan Principal		$ 115,000
Loan Principal Issuable Percent		0.0435%
Shares Issuance Frequency		Monthly
Loan One [Member]
Short-Term Debt [Line Items]
Debt Instrument, Maturity Date		Sep. 30, 2020
Loans 2 [Member]
Short-Term Debt [Line Items]
Debt Instrument, Issuance Date		Sep. 21, 2020
Loan Principal		$ 345,000
Loan Principal Issuable Percent		0.0362%
Debt Instrument, Maturity Date		Nov. 16, 2020
Shares Issuance Frequency		Weekly
Loans 3 [Member]
Short-Term Debt [Line Items]
Debt Instrument, Issuance Date		Oct. 22, 2020
Loan Principal		$ 115,000
Loan Principal Issuable Percent		0.0652%
Debt Instrument, Maturity Date		Dec. 01, 2020
Shares Issuance Frequency		Weekly
Loans 4 [Member]
Short-Term Debt [Line Items]
Debt Instrument, Issuance Date		Oct. 21, 2021
Loan Principal		$ 189,750
Loan Principal Issuable Percent		0.0435%
Debt Instrument, Maturity Date		Jan. 02, 2022
Shares Issuance Frequency		Monthly
Loans Five [Member]
Short-Term Debt [Line Items]
Debt Instrument, Issuance Date		Nov. 01, 2021
Loan Principal		$ 189,750
Loan Principal Issuable Percent		0.0435%
Debt Instrument, Maturity Date		Jan. 02, 2022
Shares Issuance Frequency		Monthly

Stockholders_ (Deficit) (Detail

Stockholders’ (Deficit) (Details Narrative) - USD ($)									3 Months Ended	12 Months Ended
	Dec. 23, 2022	Dec. 16, 2022	Dec. 23, 2020	Dec. 23, 2014	May 20, 2013	Jan. 04, 2013	Nov. 15, 2012	Nov. 11, 2011	Feb. 12, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 12, 2013	Dec. 28, 2012
Class of Stock [Line Items]
Issuance warrants, shares										10,000
Common stock, par value										$ 0.01	$ 0.01
Adjusted beneficial conversion feature value for deemed dividend											$ 1,320,331
Options to acquire shares outstanding										17,586,591	17,540,209	15,790,603
Unrecognized compensation cost										$ 15,312	$ 140,455
Number of share options exercised										25,279	208,911
Fair value of stock options										$ 17,443	$ 14,773
Number of common stock for services rendered, shares										255,500	333,200
Number of common stock for services rendered, shares										$ 392,175	$ 794,562
Number of shares issued for debt extensions										1,423,800
Value of stock issued for debt extensions										$ 2,198,861
Number of shares issued for conversion of debt										181,918
Value of shares issued for conversion of debt									$ 9,390,000	$ 467,092	$ 2,989,990
Number of shares issued for conversion of preferred stock										4,400
Value of stock issued for dividends paid in kind										$ 2,943,139
Number of shares issued for debt										659,000
Conversion of stock, amount issued										$ 873,854
Class of Warrant or Right, Number of Securities Called by Warrants or Rights											36,290
Stock Issued During Period, Value, New Issues										$ 2,198,861
Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price										$ 0.72
[custom:StockIssuedWithDebt]										$ 873,854	$ 646,718
Interest expenses debt										$ 2,700,000	6,288,529
Debt Instrument, Description			we are obligated to issue 100,000 warrants if the loan is not repaid before January 23, 2021 and an additional 10,000 shares of common stock and 100,000 warrants if the loan is not repaid before February 23, 2021. We are also obligated to issue 10,000 shares of common stock and 200,000 warrants if the loan is not repaid before March 23, 2021. During the year ended December 31, 2021 the Company issued 400,000 warrants to this lender ($3.50 exercise price and five-year term) with a fair value of $600,298. The Company is also obligated to issue 10,000 shares of common stock to this lender every 31 days up to the loan’s maturity date on June 23, 2021.
Conversion										$ 2.50
Professional Services [Member]
Class of Stock [Line Items]
Number of common stock for services rendered, shares										57,500
Number of common stock for services rendered, shares										$ 54,496
Lender [Member]
Class of Stock [Line Items]
Fair value of warrants											$ 600,298
Warrant, shares											400,000
Price per shares											$ 3.50
Lenders [Member]
Class of Stock [Line Items]
Warrants term											3 years
Strike price, per share											$ 3.5
Number of warrants issued											71,042
[custom:WarrantsIssuedForDebtSettlement]											$ 107,275
Holder [Member]
Class of Stock [Line Items]
Issuance warrants, shares	8,250	8,250
Unvested Stock-Based Awards [Member]
Class of Stock [Line Items]
Unrecognized compensation cost										$ 15,312	$ 140,455
Weighted average period										1 year 1 month 2 days	1 year 1 month 2 days
Share price										$ 1.30	$ 2.31
Options outstanding and exercisable intrinsic value											$ 0
Share-Based Payment Arrangement, Option [Member]
Class of Stock [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance													3,000,000
Other Plans [Member]
Class of Stock [Line Items]
Options to acquire shares outstanding										1,307,822
Investor Warrants [Member]
Class of Stock [Line Items]
Warrant to purchase shares of common stock											406,000
Fair value of warrants											$ 509,130
Warrant [Member]
Class of Stock [Line Items]
Strike price, per share										$ 3.50
Issuance warrants, shares										277,500	2,235,408
Fair value of warrants										$ 280,608	$ 2,400,000
Adjusted beneficial conversion feature value for deemed dividend
Options to acquire shares outstanding										16,278,769	16,207,108	14,434,702
Weighted average remaining contractual term										1 year 6 months 10 days	2 years 4 months 20 days
Number of share options exercised											187,500
Fair value of stock options
Number of common stock for services rendered, shares
Value of shares issued for conversion of debt
Class of Warrant or Right, Number of Securities Called by Warrants or Rights											1,146,945
Stock Issued During Period, Value, New Issues
[custom:StockIssuedWithDebt]
Warrant [Member] | New Conversion Debt [Member]
Class of Stock [Line Items]
Convertible shares issued										120,000
Convertible debt fair value										$ 93,576
Warrant issued for debt extension										100,000
Warrant issued for debt extension, value										$ 132,537
Warrant [Member] | Unvested Stock-Based Awards [Member]
Class of Stock [Line Items]
Options outstanding and exercisable intrinsic value											2,124,104
Common Stock [Member]
Class of Stock [Line Items]
Issuance warrants, shares										1,423,800
Adjusted beneficial conversion feature value for deemed dividend
Number of share options exercised										25,279	21,411
Fair value of stock options										$ 253	$ 214
Number of common stock for services rendered, shares										255,500	333,200
Number of common stock for services rendered, shares										$ 2,555	$ 3,332
Number of shares issued for conversion of debt										181,918	1,195,996
Value of shares issued for conversion of debt										$ 1,819	$ 11,960
Sale of common stock with fair value										25,000
Stock Issued During Period, Value, New Issues										$ 14,238
[custom:StockIssuedWithDebtShares]										659,000	399,650
[custom:StockIssuedWithDebt]										$ 6,590	$ 3,996
Common stock issuances [Member]
Class of Stock [Line Items]
Shares, Issued											10,000
Minimum [Member] | Warrant [Member]
Class of Stock [Line Items]
Debt term										3 years	3 years
Conversion											$ 3.50
Minimum [Member] | Common Stock [Member]
Class of Stock [Line Items]
Warrants term											3 years
Strike price, per share											$ 3.50
Maximum [Member] | Warrant [Member]
Class of Stock [Line Items]
Debt term										5 years	5 years
Conversion											$ 5
Maximum [Member] | Common Stock [Member]
Class of Stock [Line Items]
Warrants term											5 years
Strike price, per share											$ 5
Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized										1,000,000
Convertible preferred stock, par value										$ 0.01
Series D Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized										850	850
Convertible preferred stock, par value								$ 0.01		$ 0.01	$ 0.01
Sale of stock								843
Preferred stock redemption amount								$ 1,000
Proceeds from issuance of private placement								$ 843,000
Conversion of Stock, Shares Converted								84		84
Warrants term								5 years
Warrant to purchase shares of common stock								21
Strike price, per share								$ 24.30
Purchase price per units sold								$ 1,000
Stock conversion price per share										$ 19.50
Convertible preferred stock, conversion percentage										300%
Average daily trading volume										50,000
Pro rate basis description										the holders of Series D Convertible Preferred Stock will have the right to participate on a pro-rata basis in up to 50% of such Subsequent Financing.
Convertible preferred stock, shares issued										300	300
Series D Convertible Preferred Stock [Member] | Business Combination [Member]
Class of Stock [Line Items]
Ownership percentage										50%
Series G Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized										240,000	240,000
Convertible preferred stock, par value							$ 0.01			$ 0.01	$ 0.01
Sale of stock							4,844
Proceeds from issuance of private placement							$ 726,600
Warrants term							3 years
Warrant to purchase shares of common stock							1
Strike price, per share							$ 15
Purchase price per units sold							$ 150
Convertible preferred stock, conversion percentage										12%
Issuance warrants, shares							1
Cumulative dividend rate percentage										4%
Percentage of shares purchased for investment										6%
Convertible preferred stock, shares issued										80,570	80,570
Series G Convertible Preferred Stock [Member] | Minimum [Member]
Class of Stock [Line Items]
Proceeds from issuance of private placement										$ 2,500,000
Purchase price per units sold										$ 22.50
Average daily trading volume										334
Investment amount										$ 100,000
Series G Convertible Preferred Stock [Member] | Maximum [Member]
Class of Stock [Line Items]
Investment amount										$ 250,000
Series H Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized						10,000				10,000	10,000			10,000
Convertible preferred stock, par value						$ 0.01				$ 0.01	$ 0.01
Conversion of Stock, Shares Converted						4
Purchase price per units sold						$ 24.08
Number of common shares exchanged						33,334
Convertible preferred stock, shares issued										10,000	10,000
Series H2 Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized				21
Convertible preferred stock, par value				$ 0.01
Conversion of Stock, Shares Converted				3,334
Purchase price per units sold				$ 7.50
Number of common shares exchanged				70,000
Convertible preferred stock, shares issued				21
Common stock, par value				$ 0.01
Series J Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized										6,250
Convertible preferred stock, par value					$ 0.01					$ 0.01	$ 0.01
Sale of stock					5,087.5
Proceeds from issuance of private placement					$ 2,034,700
Conversion of Stock, Shares Converted										34
Warrant to purchase shares of common stock					34
Strike price, per share					$ 12
Purchase price per units sold					$ 400					$ 24
Average daily trading volume										1,667
Cumulative dividend rate percentage										400%
Percentage of shares purchased for investment										600%
Series J Convertible Preferred Stock [Member] | Minimum [Member]
Class of Stock [Line Items]
Investment amount										$ 250,000
Series J Convertible Preferred Stock [Member] | Maximum [Member]
Class of Stock [Line Items]
Investment amount										$ 50,000
Series K Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized										15,000	15,000
Convertible preferred stock, par value										$ 0.01	$ 0.01
Conversion of Stock, Shares Converted										34
Purchase price per units sold										$ 24
Percentage of shares purchased for investment										600%
Convertible preferred stock, shares issued										6,880
Series K Convertible Preferred Stock [Member] | Minimum [Member]
Class of Stock [Line Items]
Proceeds from issuance of private placement										$ 2,500,000
Investment amount										$ 100,000
Series AA Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized										10,000	10,000
Convertible preferred stock, par value										$ 0.01	$ 0.01
Conversion of Stock, Shares Converted										4,400
Issuance warrants, shares											82,373
Convertible preferred stock, shares issued										8,645	8,649
Accrued dividend										$ 1,727,275	$ 1,658,175
Number of shares issued for conversion of debt											1,195,996
Value of shares issued for conversion of debt											$ 2,989,990
Number of shares issued for dividends paid in kind										236,221
Value of stock issued for dividends paid in kind										$ 386,300
Number of shares issued for interest paid in kind										1,766,266
Stock Issued During Period, Value, New Issues											$ 184,274
[custom:DividendOnConvertiblePreferredStock]											800%
Series AA Convertible Preferred Stock [Member] | Lenders [Member]
Class of Stock [Line Items]
Value of shares issued for conversion of debt											$ 1,400,000
Series AA Convertible Preferred Stock [Member] | Share-Based Payment Arrangement, Option [Member]
Class of Stock [Line Items]
Number of share options exercised											21,411
Series AA Convertible Preferred Stock [Member] | Common Stock [Member]
Class of Stock [Line Items]
Issuance warrants, shares											2,883,282
Stock Issued During Period, Value, New Issues											$ 6,665,656
Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price											$ 0.69
Series AA Convertible Preferred Stock [Member] | Securities Purchase Agreement [Member] | Accredited Investors [Member]
Class of Stock [Line Items]
Sale of stock											406
Warrant to purchase shares of common stock											406,000
Strike price, per share											$ 3.50
Common stock, par value											$ 0.01
Number of preferred stock issued upon conversion											1,000
Sale of stock, amount											$ 1,015,000
Series AA Preferred Stock [Member]
Class of Stock [Line Items]
Warrants term											5 years
Warrant to purchase shares of common stock												200,100
Strike price, per share											$ 3.50
Issuance warrants, shares											200
Number of shares issued upon conversion, value											$ 509,130
Fair value of warrants											245,635
Losses on extinguishment											23,004
Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Adjusted beneficial conversion feature value for deemed dividend										$ 0	$ 873,798

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)							3 Months Ended		12 Months Ended
	May 31, 2023	Feb. 28, 2023	Jan. 20, 2023	Jan. 18, 2023	Jan. 18, 2023	Dec. 23, 2020	Mar. 31, 2023	Feb. 12, 2020	Dec. 31, 2022	Dec. 31, 2021	Aug. 31, 2021
Subsequent Event [Line Items]
Value issued								$ 9,390,000	$ 467,092	$ 2,989,990
Common stock, par value									$ 0.01	$ 0.01
Principal balance								$ 1,535,500	$ 12,000,000		$ 9,393,150
New issuance, value									$ 2,198,861
Common stock issued for debt extension, shares									10,000
Debt instrument description						we are obligated to issue 100,000 warrants if the loan is not repaid before January 23, 2021 and an additional 10,000 shares of common stock and 100,000 warrants if the loan is not repaid before February 23, 2021. We are also obligated to issue 10,000 shares of common stock and 200,000 warrants if the loan is not repaid before March 23, 2021. During the year ended December 31, 2021 the Company issued 400,000 warrants to this lender ($3.50 exercise price and five-year term) with a fair value of $600,298. The Company is also obligated to issue 10,000 shares of common stock to this lender every 31 days up to the loan’s maturity date on June 23, 2021.
Maturity date									May 02, 2023
Shares issued									181,918
Conversion fees									$ 873,854
Warrants to acquire common stock										36,290
Preferred Stock [Member]
Subsequent Event [Line Items]
Value issued
New issuance, value
Common Stock [Member]
Subsequent Event [Line Items]
Value issued									1,819	$ 11,960
New issuance, value									$ 14,238
Common stock issued for debt extension, shares									1,423,800
Shares issued									181,918	1,195,996
Subsequent Event [Member]
Subsequent Event [Line Items]
Vesting rights, description					All directors’ stock options vested 100% on the day of grant and all officers and employees stock options vested 25% on the day of grant and the remaining 75% vested equally over the subsequent thirty-six (36) months. Consultant’s Non-Qualified Stock Options vest equally per month over the subsequent twelve months.
Value issued				$ 509,032
Preferred stock, per share		$ 2.50
Common stock, par value		$ 0.01
Principal balance				$ 302,482	$ 302,482
Common stock issued for debt extension, shares	2,500
Converted shares		101,154
Debt instrument description							From January 1, 2023, through March 31, 2023, the Company issued ten (10) convertible loans for approximately $2,900,000, which each carry a 10-40% annual interest rate and four (4) to twelve (12) month terms and convertible to the Company’s common stock at a $2.50 conversion price. The Company issued 618,150 common stock and 325,000 preferred stock along with the loan issuance. In this period, the Company also borrowed $55,000 from related parties with 10% original issue discount and 10% per month interest rate and entered into seven (7) new Merchant Cash lender agreements with an original total outstanding balance of $1,498,769 and obligated the Company to pay $60,157 each week to the lenders.
Loans	$ 26,000		$ 460,000
Maturity date	Mar. 01, 2023		Jan. 03, 2023
Shares issued				203,613
Accrued interest				$ 206,050	$ 206,050
Conversion fees				$ 500
Strike price				$ 3.50	$ 3.50
Subsequent Event [Member] | Two Investor [Member]
Subsequent Event [Line Items]
Common stock issued for debt extension, shares				40,000
Subsequent Event [Member] | Investor [Member]
Subsequent Event [Line Items]
Common stock issued for debt extension, shares				884,000
Strike price				$ 2.50	$ 2.50
Warrants to acquire common stock				100,000	100,000
Subsequent Event [Member] | Preferred Stock [Member]
Subsequent Event [Line Items]
Value issued		$ 25,000
Subsequent Event [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Value issued		$ 10,000
Common stock issued for debt extension, shares		493,540
Subsequent Event [Member] | Director and Consultant [Member]
Subsequent Event [Line Items]
Non-qualified stock options, issuance					1,530,944
Subsequent Event [Member] | Officer and Employee [Member]
Subsequent Event [Line Items]
Non-qualified stock options, issuance					699,540
Warrant exercise price per share				$ 1.50	$ 1.50
Vesting percentage					100%
Grants vesting percentage					25%
Remaining vesting percentage					75%
Subsequent Event [Member] | Investor [Member] | Series A Preferred Stock [Member]
Subsequent Event [Line Items]
Unpaid accrued dividends		$ 6,226,125
Subsequent Event [Member] | Investor [Member] | Secured Convertible Promissory Notes [Member]
Subsequent Event [Line Items]
Unpaid accrued dividends		$ 2,255,587
Subsequent Event [Member] | Investor [Member] | Convertible Preferred Stock [Member]
Subsequent Event [Line Items]
Common stock issued for debt extension, shares		400.6885
Subsequent Event [Member] | Investor [Member] | Convertible Common Stock [Member]
Subsequent Event [Line Items]
Common stock issued for debt extension, shares		4,000,000
Subsequent Event [Member] | Investor [Member] | Preferred Stock [Member]
Subsequent Event [Line Items]
New issuance, value		$ 10,017,212
Common stock issued for debt extension, shares		400.6885